



Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 15

ISBN
978-0-309-29122-4

294 pages
6 x 9
PAPERBACK (2013)

Committee on Acute Exposure Guideline Levels; Committee on Toxicology; Board on Environmental Studies and Toxicology; Division on Earth and Life Studies; National Research Council

 Add book to cart

 Find similar titles

 Share this PDF



Visit the National Academies Press online and register for...

- ✓ Instant access to free PDF downloads of titles from the
 - NATIONAL ACADEMY OF SCIENCES
 - NATIONAL ACADEMY OF ENGINEERING
 - INSTITUTE OF MEDICINE
 - NATIONAL RESEARCH COUNCIL
- ✓ 10% off print titles
- ✓ Custom notification of new releases in your field of interest
- ✓ Special offers and discounts

Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Request reprint permission for this book

Acute Exposure Guideline Levels for Selected Airborne Chemicals

VOLUME 15

Committee on Acute Exposure Guideline Levels

Committee on Toxicology

Board on Environmental Studies and Toxicology

Division on Earth and Life Studies

NATIONAL RESEARCH COUNCIL
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C.
www.nap.edu

THE NATIONAL ACADEMIES PRESS 500 FIFTH STREET, NW WASHINGTON, DC 20001

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This project was supported by Contract No. W81K04-11-D-0017 and EP-W-09-007 between the National Academy of Sciences and the U.S. Department of Defense and the U.S. Environmental Protection Agency. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

International Standard Book Number-13: 978-0-309-29122-4

International Standard Book Number-10: 0-309-29122-4

Additional copies of this report are available for sale from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; <http://www.nap.edu/>.

Copyright 2013 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The **National Academy of Sciences** is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The **National Academy of Engineering** was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. C. D. Mote, Jr., is president of the National Academy of Engineering.

The **Institute of Medicine** was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The **National Research Council** was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy's purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. C. D. Mote, Jr., are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

COMMITTEE ON ACUTE EXPOSURE GUIDELINE LEVELS

Members

EDWARD C. BISOHP (*Chair*), HDR Engineering, Inc., Omaha, NE
DEEPAK K. BHALLA, Wayne State University, Detroit, MI
LUNG CHI CHEN, New York University, Tuxedo
KATHLEEN L. GABRIELSON, Johns Hopkins School of Medicine,
Baltimore, MD
GUNNAR JOHANSON, Karolinska Institute, Stockholm, Sweden
MARGARET M. MACDONELL, Argonne National Laboratory, Argonne, IL
DAVID A. MACYS, U.S. Department of the Navy (retired), Oak Harbor, WA
MARIA T. MORANDI, University of Montana, Missoula
LEENA A. NYLANDER-FRENCH, University of North Carolina, Chapel Hill, NC
FRANZ OESCH, University of Mainz (retired), Mainz, Germany
NU-MAY RUBY REED, California Environmental Protection Agency
(retired), Davis
GEORGE C. RODGERS, University of Louisville, Louisville, KY
ROBERT SNYDER, Rutgers University, Piscataway, NJ
KENNETH R. STILL, Portland State University, Portland, OR

Staff

SUSAN N.J. MARTEL, Senior Program Officer
TAMARA DAWSON, Program Associate
MIRSADA KARALIC-LONCAREVIC, Manager, Technical Information Center
RADIAH ROSE, Manager, Editorial Projects

Sponsors

U.S. DEPARTMENT OF DEFENSE
U.S. ENVIRONMENTAL PROTECTION AGENCY

COMMITTEE ON TOXICOLOGY

Members

GARY P. CARLSON (*Chair*), Purdue University (retired), West Lafayette, IN
LAWRENCE S. BETTS, Eastern Virginia Medical School, Norfolk
DEEPAK K. BHALLA, Wayne State University, Detroit, MI
DEBORAH A. CORY-SLECHTA, University of Rochester School of Medicine
and Dentistry, Rochester, NY
MARY E. DAVIS, West Virginia University, Morgantown
DAVID C. DORMAN, North Carolina State University, Raleigh
MARGARET M. MACDONELL, Argonne National Laboratory, Argonne, IL
IVAN RUSYN, University of North Carolina, Chapel Hill, NC
KENNETH R. STILL, Portland State University, Portland, OR
JOYCE S. TSUJI, Exponent, Inc., Bellevue, WA

Staff

SUSAN N.J. MARTEL, Senior Program Officer for Toxicology
MIRSADA KARALIC-LONCAREVIC, Manager, Technical Information Center
RADIAH ROSE, Manager, Editorial Projects
TAMARA DAWSON, Program Associate

BOARD ON ENVIRONMENTAL STUDIES AND TOXICOLOGY¹

Members

ROGENE F. HENDERSON (*Chair*), Lovelace Respiratory Research Institute, Albuquerque, NM
PRAVEEN AMAR, Clean Air Task Force, Boston, MA
DR. RICHARD A. BECKER, American Chemistry Council, Washington, DC
MICHAEL J. BRADLEY, M.J. Bradley & Associates, Concord, MA
JONATHAN Z. CANNON, University of Virginia, Charlottesville
GAIL CHARNLEY, HealthRisk Strategies, Washington, DC
DAVID C. DORMAN, Department of Molecular Biomedical Sciences, Raleigh, NC
CHARLES T. DRISCOLL, JR., Syracuse University, New York
WILLIAM H. FARLAND, Colorado State University, Fort Collins, CO
LYNN R. GOLDMAN, George Washington University, Washington, DC
LINDA E. GREER, Natural Resources Defense Council, Washington, DC
WILLIAM E. HALPERIN, University of Medicine and Dentistry of New Jersey, Newark
STEVEN P. HAMBURG, Environmental Defense Fund, New York, NY
ROBERT A. HIATT, University of California, San Francisco
PHILIP K. HOPKE, Clarkson University, Potsdam, NY
SAMUEL KACEW, University of Ottawa, Ontario
H. SCOTT MATTHEWS, Carnegie Mellon University, Pittsburgh, PA
THOMAS E. MCKONE, University of California, Berkeley
TERRY L. MEDLEY, E.I. du Pont de Nemours & Company, Wilmington, DE
JANA MILFORD, University of Colorado at Boulder, Boulder
MARK A. RATNER, Northwestern University, Evanston, IL
JOAN B. ROSE, Michigan State University, East Lansing, MI
GINA M. SOLOMON, California Environmental Protection Agency, Sacramento, CA
PETER S. THORNE, University of Iowa, Iowa City, IA
DOMINIC M. DI TORO, University of Delaware Newark, DE
JOYCE S. TSUJI, Exponent Environmental Group, Bellevue, WA

Senior Staff

JAMES J. REISA, Director
DAVID J. POLICANSKY, Scholar
RAYMOND A. WASSEL, Senior Program Officer for Environmental Studies
ELLEN K. MANTUS, Senior Program Officer for Risk Analysis
SUSAN N.J. MARTEL, Senior Program Officer for Toxicology
EILEEN N. ABT, Senior Program Officer
MIRSADA KARALIC-LONCAREVIC, Manager, Technical Information Center
RADIAH ROSE, Manager, Editorial Projects

¹This study was planned, overseen, and supported by the Board on Environmental Studies and Toxicology.

**OTHER REPORTS OF THE BOARD ON
ENVIRONMENTAL STUDIES AND TOXICOLOGY**

Assessing Risks to Endangered and Threatened Species from Pesticides (2013)
Science for Environmental Protection: The Road Ahead (2012)
Exposure Science in the 21st Century: A Vision and A Strategy (2012)
A Research Strategy for Environmental, Health, and Safety Aspects of
Engineered Nanomaterials (2012)
Macondo Well–Deepwater Horizon Blowout: Lessons for Improving Offshore
Drilling Safety (2012)
Feasibility of Using Mycoherbicides for Controlling Illicit Drug Crops (2011)
Improving Health in the United States: The Role of Health Impact
Assessment (2011)
A Risk-Characterization Framework for Decision-Making at the Food and
Drug Administration (2011)
Review of the Environmental Protection Agency’s Draft IRIS Assessment of
Formaldehyde (2011)
Toxicity-Pathway-Based Risk Assessment: Preparing for Paradigm Change (2010)
The Use of Title 42 Authority at the U.S. Environmental Protection Agency (2010)
Review of the Environmental Protection Agency’s Draft IRIS Assessment of
Tetrachloroethylene (2010)
Hidden Costs of Energy: Unpriced Consequences of Energy Production and
Use (2009)
Contaminated Water Supplies at Camp Lejeune—Assessing Potential Health
Effects (2009)
Review of the Federal Strategy for Nanotechnology-Related Environmental,
Health, and Safety Research (2009)
Science and Decisions: Advancing Risk Assessment (2009)
Phthalates and Cumulative Risk Assessment: The Tasks Ahead (2008)
Estimating Mortality Risk Reduction and Economic Benefits from Controlling
Ozone Air Pollution (2008)
Respiratory Diseases Research at NIOSH (2008)
Evaluating Research Efficiency in the U.S. Environmental Protection Agency (2008)
Hydrology, Ecology, and Fishes of the Klamath River Basin (2008)
Applications of Toxicogenomic Technologies to Predictive Toxicology and Risk
Assessment (2007)
Models in Environmental Regulatory Decision Making (2007)
Toxicity Testing in the Twenty-first Century: A Vision and a Strategy (2007)
Sediment Dredging at Superfund Megasites: Assessing the Effectiveness (2007)
Environmental Impacts of Wind-Energy Projects (2007)
Scientific Review of the Proposed Risk Assessment Bulletin from the Office of
Management and Budget (2007)
Assessing the Human Health Risks of Trichloroethylene: Key Scientific
Issues (2006)
New Source Review for Stationary Sources of Air Pollution (2006)
Human Biomonitoring for Environmental Chemicals (2006)

Health Risks from Dioxin and Related Compounds: Evaluation of the EPA Reassessment (2006)
Fluoride in Drinking Water: A Scientific Review of EPA's Standards (2006)
State and Federal Standards for Mobile-Source Emissions (2006)
Superfund and Mining Megasites—Lessons from the Coeur d'Alene River Basin (2005)
Health Implications of Perchlorate Ingestion (2005)
Air Quality Management in the United States (2004)
Endangered and Threatened Species of the Platte River (2004)
Atlantic Salmon in Maine (2004)
Endangered and Threatened Fishes in the Klamath River Basin (2004)
Cumulative Environmental Effects of Alaska North Slope Oil and Gas Development (2003)
Estimating the Public Health Benefits of Proposed Air Pollution Regulations (2002)
Biosolids Applied to Land: Advancing Standards and Practices (2002)
The Airliner Cabin Environment and Health of Passengers and Crew (2002)
Arsenic in Drinking Water: 2001 Update (2001)
Evaluating Vehicle Emissions Inspection and Maintenance Programs (2001)
Compensating for Wetland Losses Under the Clean Water Act (2001)
A Risk-Management Strategy for PCB-Contaminated Sediments (2001)
Acute Exposure Guideline Levels for Selected Airborne Chemicals (fourteen volumes, 2000-2013)
Toxicological Effects of Methylmercury (2000)
Strengthening Science at the U.S. Environmental Protection Agency (2000)
Scientific Frontiers in Developmental Toxicology and Risk Assessment (2000)
Ecological Indicators for the Nation (2000)
Waste Incineration and Public Health (2000)
Hormonally Active Agents in the Environment (1999)
Research Priorities for Airborne Particulate Matter (four volumes, 1998-2004)
The National Research Council's Committee on Toxicology: The First 50 Years (1997)
Carcinogens and Anticarcinogens in the Human Diet (1996)
Upstream: Salmon and Society in the Pacific Northwest (1996)
Science and the Endangered Species Act (1995)
Wetlands: Characteristics and Boundaries (1995)
Biologic Markers (five volumes, 1989-1995)
Science and Judgment in Risk Assessment (1994)
Pesticides in the Diets of Infants and Children (1993)
Dolphins and the Tuna Industry (1992)
Science and the National Parks (1992)
Human Exposure Assessment for Airborne Pollutants (1991)
Rethinking the Ozone Problem in Urban and Regional Air Pollution (1991)
Decline of the Sea Turtles (1990)

*Copies of these reports may be ordered from the National Academies Press
(800) 624-6242 or (202) 334-3313
www.nap.edu*

OTHER REPORTS OF THE COMMITTEE ON TOXICOLOGY

- Potential Health Risks to DOD Firing-Range Personnel from Recurrent Lead Exposure (2012)
- Review of Studies of Possible Toxic Effects from Past Environmental Contamination at Fork Detrick: A Letter Report (2012)
- Review of Risk Assessment Work Plan for the Medical Countermeasures Test and Evaluation Facility at Fort Detrick, A Letter Report (2011)
- Assistance to the U.S. Army Medical Research and Materiel Command with Preparation of a Risk Assessment for the Medical Countermeasures Test and Evaluation (MCMT&E) Facility at Fort Detrick, Maryland, A Letter Report (2011)
- Review of the Department of Defense Enhanced Particulate Matter Surveillance Program Report (2010)
- Evaluation of the Health and Safety Risks of the New USAMRIID High-Containment Facilities at Fort Detrick, Maryland (2010)
- Combined Exposures to Hydrogen Cyanide and Carbon Monoxide in Army Operations: Final Report (2008)
- Managing Health Effects of Beryllium Exposure (2008)
- Review of Toxicologic and Radiologic Risks to Military Personnel from Exposures to Depleted Uranium (2008)
- Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants, Volume 1 (2007), Volume 2 (2008)
- Review of the Department of Defense Research Program on Low-Level Exposures to Chemical Warfare Agents (2005)
- Review of the Army's Technical Guides on Assessing and Managing Chemical Hazards to Deployed Personnel (2004)
- Spacecraft Water Exposure Guidelines for Selected Contaminants, Volume 1 (2004), Volume 2 (2007), Volume 3 (2008)
- Toxicologic Assessment of Jet-Propulsion Fuel 8 (2003)
- Review of Submarine Escape Action Levels for Selected Chemicals (2002)
- Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals (2001)
- Evaluating Chemical and Other Agent Exposures for Reproductive and Developmental Toxicity (2001)
- Acute Exposure Guideline Levels for Selected Airborne Contaminants, Volume 1 (2000), Volume 2 (2002), Volume 3 (2003), Volume 4 (2004), Volume 5 (2007), Volume 6 (2008), Volume 7 (2009), Volume 8 (2009), Volume 9 (2010), Volume 10 (2011), Volume 11 (2012), Volume 13 (2012), Volume 14 (2013)
- Review of the U.S. Navy's Human Health Risk Assessment of the Naval Air Facility at Atsugi, Japan (2000)
- Methods for Developing Spacecraft Water Exposure Guidelines (2000)
- Review of the U.S. Navy Environmental Health Center's Health-Hazard Assessment Process (2000)
- Review of the U.S. Navy's Exposure Standard for Manufactured Vitreous Fibers (2000)
- Re-Evaluation of Drinking-Water Guidelines for Diisopropyl Methylphosphonate (2000)
- Submarine Exposure Guidance Levels for Selected Hydrofluorocarbons: HFC-236fa, HFC-23, and HFC-404a (2000)

Review of the U.S. Army's Health Risk Assessments for Oral Exposure to Six
Chemical-Warfare Agents (1999)
Toxicity of Military Smokes and Obscurants, Volume 1(1997), Volume 2 (1999),
Volume 3 (1999)
Assessment of Exposure-Response Functions for Rocket-Emission Toxicants (1998)
Toxicity of Alternatives to Chlorofluorocarbons: HFC-134a and HCFC-123 (1996)
Permissible Exposure Levels for Selected Military Fuel Vapors (1996)
Spacecraft Maximum Allowable Concentrations for Selected Airborne Contaminants,
Volume 1 (1994), Volume 2 (1996), Volume 3 (1996), Volume 4 (2000),
Volume 5 (2008)

Preface

Extremely hazardous substances (EHSs)² can be released accidentally as a result of chemical spills, industrial explosions, fires, or accidents involving railroad cars and trucks transporting EHSs. Workers and residents in communities surrounding industrial facilities where EHSs are manufactured, used, or stored and in communities along the nation's railways and highways are potentially at risk of being exposed to airborne EHSs during accidental releases or intentional releases by terrorists. Pursuant to the Superfund Amendments and Reauthorization Act of 1986, the U.S. Environmental Protection Agency (EPA) has identified approximately 400 EHSs on the basis of acute lethality data in rodents.

As part of its efforts to develop acute exposure guideline levels for EHSs, EPA and the Agency for Toxic Substances and Disease Registry (ATSDR) in 1991 requested that the National Research Council (NRC) develop guidelines for establishing such levels. In response to that request, the NRC published *Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances* in 1993. Subsequently, *Standard Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Substances* was published in 2001, providing updated procedures, methodologies, and other guidelines used by the National Advisory Committee (NAC) on Acute Exposure Guideline Levels for Hazardous Substances and the Committee on Acute Exposure Guideline Levels (AEGLs) in developing the AEGL values.

Using the 1993 and 2001 NRC guidelines reports, the NAC—consisting of members from EPA, the Department of Defense (DOD), the Department of Energy (DOE), the Department of Transportation (DOT), other federal and state governments, the chemical industry, academia, and other organizations from the private sector—has developed AEGLs for more than 270 EHSs.

In 1998, EPA and DOD requested that the NRC independently review the AEGLs developed by NAC. In response to that request, the NRC organized within its Committee on Toxicology (COT) the Committee on Acute Exposure Guideline Levels, which prepared this report. This report is the fifteenth volume

²As defined pursuant to the Superfund Amendments and Reauthorization Act of 1986.

in that series. AEGL documents for ethyl mercaptan, methyl mercaptan, phenyl mercaptan, tert-octyl mercaptan, lewisite, methyl isothiocyanate, and selected monoisocyanates are each published as an appendix in this report. The committee concludes that the AEGLs developed in these appendixes are scientifically valid conclusions based on the data reviewed by NAC and are consistent with the NRC guideline reports. AEGL reports for additional chemicals will be presented in subsequent volumes.

The committee's review of the AEGL documents involved both oral and written presentations to the committee by the authors of the documents. The committee examined the draft documents and provided comments and recommendations for how they could be improved in a series of interim reports. The authors revised the draft AEGL documents based on the advice in the interim reports and presented them for reexamination by the committee as many times as necessary until the committee was satisfied that the AEGLs were scientifically justified and consistent with the 1993 and 2001 NRC guideline reports. After these determinations have been made for an AEGL document, it is published as an appendix in a volume such as this one.

The interim reports of the committee that led to this report were reviewed in draft form by individuals selected for their diverse perspectives and technical expertise, in accordance with procedures approved by the NRC's Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following individuals for their review of the committee interim reports, which summarize the committee's conclusions and recommendations for improving NAC's AEGL documents for ethyl mercaptan (interim reports 19a, 20a, and 21a), methyl mercaptan (interim reports 15, 19a, 20a, and 21a), phenyl mercaptan (interim reports 19a, 20a, and 21a), tert-octyl mercaptan (interim reports 19a, 20a, and 21a), lewisite (interim reports 19a and 21a), methyl isothiocyanate (interim reports 20a and 21a), and selected monoisocyanates (interim reports 20a, 20b, 21a): Harvey Clewell (The Hamner Institutes for Health Sciences), Jeffrey Fisher (U.S. Food and Drug Administration), Sam Kacew (University of Ottawa), A. Wallace Hayes (Harvard School of Public Health), Rogene Henderson (Lovelace Respiratory Research Institute [retired]), James McDougal (Wright State University [retired]), and Judith Zelikoff (New York University).

Although the reviewers listed above have provided many constructive comments and suggestions, they were not asked to endorse the conclusions or recommendations, nor did they see the final draft of this volume before its release. The review of interim reports was overseen by Robert Goyer (University of Western Ontario [retired]). Appointed by the NRC, he was responsible for making certain that an independent examination of the interim reports was carried out in accordance with institutional procedures and that all review com-

Preface

xv

ments were carefully considered. Responsibility for the final content of this report rests entirely with the authoring committee and the institution.

The committee gratefully acknowledges the valuable assistance provided by Ernest Falke and Iris A. Camacho from EPA. The committee also acknowledges Susan Martel, the project director for her work this project. Other staff members who contributed to this effort are James J. Reisa (director of the Board on Environmental Studies and Toxicology), Radiah Rose (manager of editorial projects), Mirsada Karalic-Loncarevic (manager of the Technical Information Center), and Tamara Dawson (program associate). Finally, I would like to thank all members of the committee for their expertise and dedicated effort throughout the development of this report.

Edward C. Bishop, *Chair*
Committee on Acute Exposure
Guideline Levels

Contents

NATIONAL RESEARCH COUNCIL COMMITTEE REVIEW OF ACUTE EXPOSURE GUIDELINE LEVELS OF SELECTED AIRBORNE CHEMICALS	3
---	----------

APPENDIXES

1 ETHYL MERCAPTAN	13
Acute Exposure Guideline Levels	
2 METHYL MERCAPTAN	44
Acute Exposure Guideline Levels	
3 PHENYL MERCAPTAN.....	75
Acute Exposure Guideline Levels	
4 tert-OCTYL MERCAPTAN	99
Acute Exposure Guideline Levels	
5 LEWISITE	130
Acute Exposure Guideline Levels	
6 METHYL ISOTHIOCYANATE	166
Acute Exposure Guideline Levels	
7 SELECTED MONOISOCYANATES	200
Acute Exposure Guideline Levels	

National Research Council Committee Review of Acute Exposure Guideline Levels of Selected Airborne Chemicals

This report is the fifteenth volume in the series *Acute Exposure Guideline Levels for Selected Airborne Chemicals*.

In the Bhopal disaster of 1984, approximately 2,000 residents living near a chemical plant were killed and 20,000 more suffered irreversible damage to their eyes and lungs following accidental release of methyl isocyanate. The toll was particularly high because the community had little idea what chemicals were being used at the plant, how dangerous they might be, or what steps to take in an emergency. This tragedy served to focus international attention on the need for governments to identify hazardous substances and to assist local communities in planning how to deal with emergency exposures.

In the United States, the Superfund Amendments and Reauthorization Act (SARA) of 1986 required that the U.S. Environmental Protection Agency (EPA) identify extremely hazardous substances (EHSs) and, in cooperation with the Federal Emergency Management Agency and the U.S. Department of Transportation, assist local emergency planning committees (LEPCs) by providing guidance for conducting health hazard assessments for the development of emergency response plans for sites where EHSs are produced, stored, transported, or used. SARA also required that the Agency for Toxic Substances and Disease Registry (ATSDR) determine whether chemical substances identified at hazardous waste sites or in the environment present a public health concern.

As a first step in assisting the LEPCs, EPA identified approximately 400 EHSs largely on the basis of their immediately dangerous to life and health values, developed by the National Institute for Occupational Safety and Health. Although several public and private groups, such as the Occupational Safety and Health Administration and the American Conference of Governmental Industrial Hygienists, have established exposure limits for some substances and some exposures (e.g., workplace or ambient air quality), these limits are not easily or directly translated into emergency exposure limits for exposures at high levels

but of short duration, usually less than 1 hour (h), and only once in a lifetime for the general population, which includes infants (from birth to 3 years of age), children, the elderly, and persons with diseases, such as asthma or heart disease.

The National Research Council (NRC) Committee on Toxicology (COT) has published many reports on emergency exposure guidance levels and spacecraft maximum allowable concentrations for chemicals used by the U.S. Department of Defense (DOD) and the National Aeronautics and Space Administration (NASA) (NRC 1968, 1972, 1984a,b,c,d, 1985a,b, 1986a, 1987, 1988, 1994, 1996a,b, 2000a, 2002a, 2007a, 2008a). COT has also published guidelines for developing emergency exposure guidance levels for military personnel and for astronauts (NRC 1986b, 1992, 2000b). Because of COT's experience in recommending emergency exposure levels for short-term exposures, in 1991 EPA and ATSDR requested that COT develop criteria and methods for developing emergency exposure levels for EHSs for the general population. In response to that request, the NRC assigned this project to the COT Subcommittee on Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances. The report of that subcommittee, *Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances* (NRC 1993), provides step-by-step guidance for setting emergency exposure levels for EHSs. Guidance is given on what data are needed, what data are available, how to evaluate the data, and how to present the results.

In November 1995, the National Advisory Committee (NAC)¹ for Acute Exposure Guideline Levels for Hazardous Substances was established to identify, review, and interpret relevant toxicologic and other scientific data and to develop acute exposure guideline levels (AEGLs) for high-priority, acutely toxic chemicals. The NRC's previous name for acute exposure levels—community emergency exposure levels (CEELs)—was replaced by the term AEGLs to reflect the broad application of these values to planning, response, and prevention in the community, the workplace, transportation, the military, and the remediation of Superfund sites.

AEGLs represent threshold exposure limits (exposure levels below which adverse health effects are not likely to occur) for the general public and are applicable to emergency exposures ranging from 10 minutes (min) to 8 h. Three levels—AEGL-1, AEGL-2, and AEGL-3—are developed for each of five exposure periods (10 min, 30 min, 1 h, 4 h, and 8 h) and are distinguished by varying degrees of severity of toxic effects. The three AEGLs are defined as follows:

¹NAC completed its chemical reviews in October 2011. The committee was composed of members from EPA, DOD, many other federal and state agencies, industry, academia, and other organizations. From 1996 to 2011, the NAC discussed over 300 chemicals and developed AEGLs values for at least 272 of the 329 chemicals on the AEGLs priority chemicals lists. Although the work of the NAC has ended, the NAC-reviewed technical support documents are being submitted to the NRC for independent review and finalization.

AEGL-1 is the airborne concentration (expressed as ppm [parts per million] or mg/m³ [milligrams per cubic meter]) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.

AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.

AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening adverse health effects or death.

Airborne concentrations below AEGL-1 represent exposure levels that can produce mild and progressively increasing but transient and non disabling odor, taste, and sensory irritation or certain asymptomatic nonsensory adverse effects. With increasing airborne concentrations above each AEGL, there is a progressive increase in the likelihood of occurrence and the severity of effects described for each corresponding AEGL. Although the AEGL values represent threshold levels for the general public, including susceptible subpopulations, such as infants, children, the elderly, persons with asthma, and those with other illnesses, it is recognized that individuals, subject to idiosyncratic responses, could experience the effects described at concentrations below the corresponding AEGL.

SUMMARY OF REPORT ON GUIDELINES FOR DEVELOPING AEGLS

As described in *Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances* (NRC 1993) and the NRC guidelines report *Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals* (NRC 2001a), the first step in establishing AEGLs for a chemical is to collect and review all relevant published and unpublished information. Various types of evidence are assessed in establishing AEGL values for a chemical. These include information from (1) chemical-physical characterizations, (2) structure-activity relationships, (3) in vitro toxicity studies, (4) animal toxicity studies, (5) controlled human studies, (6) observations of humans involved in chemical accidents, and (7) epidemiologic studies. Toxicity data from human studies are most applicable and are used when available in preference to data from animal studies and in vitro studies. Toxicity data from inhalation exposures are most useful for setting AEGLs for airborne chemicals because inhalation is the most likely route of exposure and because extrapolation of data from other routes would lead to additional uncertainty in the AEGL estimate.

For most chemicals, actual human toxicity data are not available or critical information on exposure is lacking, so toxicity data from studies conducted in laboratory animals are extrapolated to estimate the potential toxicity in humans. Such extrapolation requires experienced scientific judgment. The toxicity data for animal species most representative of humans in terms of pharmacodynamic and pharmacokinetic properties are used for determining AEGLs. If data are not available on the species that best represents humans, data from the most sensitive animal species are used. Uncertainty factors are commonly used when animal data are used to estimate risk levels for humans. The magnitude of uncertainty factors depends on the quality of the animal data used to determine the no-observed-adverse-effect level (NOAEL) and the mode of action of the substance in question. When available, pharmacokinetic data on tissue doses are considered for interspecies extrapolation.

For substances that affect several organ systems or have multiple effects, all end points (including reproductive [in both genders], developmental, neurotoxic, respiratory, and other organ-related effects) are evaluated, the most important or most sensitive effect receiving the greatest attention. For carcinogenic chemicals, excess carcinogenic risk is estimated, and the AEGLs corresponding to carcinogenic risks of 1 in 10,000 (1×10^{-4}), 1 in 100,000 (1×10^{-5}), and 1 in 1,000,000 (1×10^{-6}) exposed persons are estimated.

REVIEW OF AEGL REPORTS

As NAC began developing chemical-specific AEGL reports, EPA and DOD asked the NRC to review independently the NAC reports for their scientific validity, completeness, and consistency with the NRC guideline reports (NRC 1993, 2001a). The NRC assigned this project to the COT Committee on Acute Exposure Guideline Levels. The committee has expertise in toxicology, epidemiology, occupational health, pharmacology, medicine, pharmacokinetics, industrial hygiene, and risk assessment.

The AEGL draft reports were initially prepared by ad hoc AEGL development teams consisting of a chemical manager, chemical reviewers, and a staff scientist of the NAC contractors—Oak Ridge National Laboratory and subsequently SRC, Inc. The draft documents were then reviewed by NAC and elevated from “draft” to “proposed” status. After the AEGL documents were approved by NAC, they were published in the *Federal Register* for public comment. The reports were then revised by NAC in response to the public comments, elevated from “proposed” to “interim” status, and sent to the NRC Committee on Acute Exposure Guideline Levels for final evaluation.

The NRC committee’s review of the AEGL reports prepared by NAC and its contractors involves oral and written presentations to the committee by the authors of the reports. The NRC committee provides advice and recommendations for revisions to ensure scientific validity and consistency with the NRC guideline reports (NRC 1993, 2001a). The revised reports are presented at subsequent meetings until the committee is satisfied with the reviews.

Because of the enormous amount of data presented in AEGL reports, the NRC committee cannot verify all of the data used by NAC. The NRC committee relies on NAC and the contractors for the accuracy and completeness of the toxicity data cited in the AEGL reports. Thus far, the committee has prepared fourteen reports in the series *Acute Exposure Guideline Levels for Selected Airborne Chemicals* (NRC 2001b, 2002b, 2003, 2004, 2007b, 2008b, 2009, 2010a,b, 2011, 2012a,b,c, 2013). This report is the fifteenth volume in that series. AEGL documents for ethyl mercaptan, methyl mercaptan, phenyl mercaptan, tert-octyl mercaptan, lewisite, methyl isothiocyanate, and selected monoisocyanates are each published as an appendix in this report. The committee concludes that the AEGLs developed in these appendixes are scientifically valid conclusions based on the data reviewed by NAC and are consistent with the NRC guideline reports. AEGL reports for additional chemicals will be presented in subsequent volumes.

REFERENCES

- NRC (National Research Council). 1968. *Atmospheric Contaminants in Spacecraft*. Washington, DC: National Academy of Sciences.
- NRC (National Research Council). 1972. *Atmospheric Contaminants in Manned Spacecraft*. Washington, DC: National Academy of Sciences.
- NRC (National Research Council). 1984a. *Emergency and Continuous Exposure Limits for Selected Airborne Contaminants, Vol. 1*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1984b. *Emergency and Continuous Exposure Limits for Selected Airborne Contaminants, Vol. 2*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1984c. *Emergency and Continuous Exposure Limits for Selected Airborne Contaminants, Vol. 3*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1984d. *Toxicity Testing: Strategies to Determine Needs and Priorities*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1985a. *Emergency and Continuous Exposure Guidance Levels for Selected Airborne Contaminants, Vol. 4*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1985b. *Emergency and Continuous Exposure Guidance Levels for Selected Airborne Contaminants, Vol. 5*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1986a. *Emergency and Continuous Exposure Guidance Levels for Selected Airborne Contaminants, Vol. 6*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1986b. *Criteria and Methods for Preparing Emergency Exposure Guidance Level (EEGL), Short-Term Public Emergency Guidance Level (SPEGL), and Continuous Exposure Guidance level (CEGL) Documents*. Washington, DC: National Academy Press.
- NRC (National Research Council). 1987. *Emergency and Continuous Exposure Guidance Levels for Selected Airborne Contaminants, Vol. 7*. Washington, DC: National Academy Press.

- NRC (National Research Council). 1988. Emergency and Continuous Exposure Guidance Levels for Selected Airborne Contaminants, Vol. 8. Washington, DC: National Academy Press.
- NRC (National Research Council). 1992. Guidelines for Developing Spacecraft Maximum Allowable Concentrations for Space Station Contaminants. Washington, DC: National Academy Press.
- NRC (National Research Council). 1993. Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances. Washington, DC: National Academy Press.
- NRC (National Research Council). 1994. Spacecraft Maximum Allowable Concentrations for Selected Airborne Contaminants, Vol. 1. Washington, DC: National Academy Press.
- NRC (National Research Council). 1996a. Spacecraft Maximum Allowable Concentrations for Selected Airborne Contaminants, Vol. 2. Washington, DC: National Academy Press.
- NRC (National Research Council). 1996b. Spacecraft Maximum Allowable Concentrations for Selected Airborne Contaminants, Vol. 3. Washington, DC: National Academy Press.
- NRC (National Research Council). 2000a. Spacecraft Maximum Allowable Concentrations for Selected Airborne Contaminants, Vol. 4. Washington, DC: National Academy Press.
- NRC (National Research Council). 2000b. Methods for Developing Spacecraft Water Exposure Guidelines. Washington, DC: National Academy Press.
- NRC (National Research Council). 2001a. Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals. Washington, DC: National Academy Press.
- NRC (National Research Council). 2001b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 1. Washington, DC: National Academy Press.
- NRC (National Research Council). 2002a. Review of Submarine Escape Action Levels for Selected Chemicals. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2002b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol 2. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2003. Acute Exposure Guideline Levels for Selected Airborne Chemical, Vol. 3. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2004. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 4. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2007a. Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants, Vol. 1. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2007b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 5. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2008a. Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants, Vol. 2. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2008b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 6. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2009. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 7. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2010a. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 8. Washington, DC: The National Academies Press.

- NRC (National Research Council). 2010b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 9. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2011. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 10. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2012a. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 11. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2012b. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 12. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2012c. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 13. Washington, DC: The National Academies Press.
- NRC (National Research Council). 2013. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Vol. 14. Washington, DC: The National Academies Press.

Appendixes

7

Selected Monoisocyanates¹

Acute Exposure Guideline Levels

PREFACE

Under the authority of the Federal Advisory Committee Act (FACA) P.L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review, and interpret relevant toxicologic and other scientific data and develop AEGLs for high-priority, acutely toxic chemicals.

AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes (min) to 8 hours (h). Three levels—AEGL-1, AEGL-2, and AEGL-3—are developed for each of five exposure periods (10 and 30 min and 1, 4, and 8 h) and are distinguished by varying degrees of severity of toxic effects. The three AEGLs are defined as follows:

AEGL-1 is the airborne concentration (expressed as parts per million or milligrams per cubic meter [ppm or mg/m³]) of a substance above which it is predicted that the general population, including susceptible individuals, could

¹This document was prepared by the AEGL Development Team composed of Robert Young and Carol Wood (Oak Ridge National Laboratory), Heather Carlson-Lynch (SRC, Inc.), Chemical Managers Susan Ripple and Marc Ruijten (National Advisory Committee [NAC] on Acute Exposure Guideline Levels for Hazardous Substances), and Ernest V. Falke (U.S. Environmental Protection Agency). The NAC reviewed and revised the document and AEGLs as deemed necessary. Both the document and the AEGL values were then reviewed by the National Research Council (NRC) Committee on Acute Exposure Guideline Levels. The NRC committee has concluded that the AEGLs developed in this document are scientifically valid conclusions based on the data reviewed by the NRC and are consistent with the NRC guidelines reports (NRC 1993, 2001).

experience notable discomfort, irritation, or certain asymptomatic, nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.

AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.

AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

Airborne concentrations below the AEGL-1 represent exposure concentrations that could produce mild and progressively increasing but transient and nondisabling odor, taste, and sensory irritation or certain asymptomatic, nonsensory effects. With increasing airborne concentrations above each AEGL, there is a progressive increase in the likelihood of occurrence and the severity of effects described for each corresponding AEGL. Although the AEGL values represent threshold concentrations for the general public, including susceptible subpopulations, such as infants, children, the elderly, persons with asthma, and those with other illnesses, it is recognized that individuals, subject to idiosyncratic responses, could experience the effects described at concentrations below the corresponding AEGL.

SUMMARY

Four monoisocyanates are considered in this chapter: ethyl isocyanate, *n*-butyl isocyanate, cyclohexyl isocyanate, and phenyl isocyanate. These monoisocyanates appear to exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate. AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived.

Data on ethyl isocyanate and cyclohexyl isocyanate were limited to rat lethality studies that used few animals, lacked analytic measurement of concentrations, and had 100% mortality at nearly all test concentrations. Because of the data limitations, AEGL-2 and AEGL-3 values were based on the AEGL values for methyl isocyanate. A comparison of the available lethality data on the three chemicals suggests that use of methyl isocyanate as a surrogate and applying a modifying factor of 2, to account for the possibility that ethyl isocyanate and cyclohexyl isocyanate might be more toxic, results in sufficiently protective AEGL values. For example, when groups of three rats were exposed to ethyl isocyanate for 6 h, all rats survived at 27 ppm and no rats survived at 82 ppm. When three rats were exposed for 6 h to cyclohexyl isocyanate at 18 ppm, one

died on day 7 post-exposure and the others were killed on day 8, presumably due to moribund condition. For comparison, the 6-h LC_{50} (lethal concentration, 50% lethality) for methyl isocyanate in rats was 6.1 ppm (NRC 2003).

Rat lethality data were adequate to derive AEGL-3 values for *n*-butyl isocyanate and phenyl isocyanate, and AEGL-2 values were estimated as one-third of the corresponding AEGL-3 values. To derive AEGL-3 values for these compounds, an interspecies uncertainty factor of 3 was applied because of the limited species variability exhibited by methyl isocyanate. A factor of 10 was applied to account for intraspecies variability, as was done for methyl isocyanate (NRC 2003). A modifying factor 3 was also applied because data on the potential developmental toxicity of *n*-butyl isocyanate and phenyl isocyanate were lacking; methyl isocyanate is a known developmental toxicant.

AEGL values for the selected monoisocyanates are presented in Table 7-1. AEGL values for methyl isocyanate and toluene diisocyanate are presented in Table 7-2 for comparison.

1. INTRODUCTION

The monoisocyanates generally occur as colorless to yellow liquids, and typically have a high vapor pressure and pungent odor. When heated, monoisocyanates decompose and form toxic fumes of hydrogen cyanide and nitrogen oxides (IPCS 1997, 2002). Cyclohexyl isocyanate decomposes in water, and unlike some isocyanates, it does not self-polymerize (Eastman Kodak 1990). The chemical and physical properties of ethyl, *n*-butyl, cyclohexyl, and phenyl isocyanate are presented in Table 7-3.

Ethyl isocyanate is used as an intermediate in the manufacture of pharmaceuticals and pesticides. It may be produced by the reaction of phosgene with amines or amine salts. The thermal cleavage of urethanes, performed using the appropriate amine, urea, and alcohol, is a common commercial production method (HSDB 2007a).

n-Butyl isocyanate is used in closed systems for the manufacture of chemicals, dyes, and pesticides (ANPON 2008). Global production of *n*-butyl isocyanate is estimated at 1,000 to 5,000 metric tons per year (OECD 2005). Phenyl isocyanate is used in the production of polymers and as an intermediate in organic syntheses (Richter 1986; Karol and Kramarik 1996).

Current use and production information for cyclohexyl isocyanate were not found.

In the sections below, general factors to consider in developing AEGL values for the selected monoisocyanates are presented first, and are followed by chemical-specific data.

TABLE 7-1 AEGL Values for Selected Monoisocyanates^a

Classification	10 min	30 min	1 h	4 h	8 h	End Point (Reference)
<i>Ethyl isocyanate</i>						
AEGL-1 (non-disabling)	NR	NR	NR	NR	NR	Insufficient warning properties; possible systemic effects at concentrations lower than those that produce irritation.
AEGL-2 (disabling)	0.20 ppm (0.58 mg/m ³)	0.065 ppm (0.19 mg/m ³)	0.034 ppm (0.099 mg/m ³)	0.0085 ppm (0.025 mg/m ³)	0.0040 ppm (0.012 mg/m ³)	Based on AEGL-2 values for methyl isocyanate
AEGL-3 (lethal)	0.60 ppm (1.7 mg/m ³)	0.20 ppm (0.58 mg/m ³)	0.10 ppm (0.29 mg/m ³)	0.025 ppm (0.073 mg/m ³)	0.013 ppm (0.038 mg/m ³)	Based on AEGL-3 values for methyl isocyanate
<i>Cyclohexyl isocyanate</i>						
AEGL-1 (non-disabling)	NR	NR	NR	NR	NR	Insufficient warning properties; possible systemic effects at concentrations lower than those that produce irritation.
AEGL-2 (disabling)	0.20 ppm (1.0 mg/m ³)	0.065 ppm (0.33 mg/m ³)	0.034 ppm (0.17 mg/m ³)	0.0085 ppm (0.043 mg/m ³)	0.0040 ppm (0.020 mg/m ³)	Based on AEGL-2 values for methyl isocyanate
AEGL-3 (lethal)	0.60 ppm (3.1 mg/m ³)	0.20 ppm (1.0 mg/m ³)	0.10 ppm (0.51 mg/m ³)	0.025 ppm (0.13 mg/m ³)	0.013 ppm (0.066 mg/m ³)	Based on AEGL-3 values for methyl isocyanate AEGL-3
<i>n-Butyl isocyanate</i>						
AEGL-1 (non-disabling)	NR	NR	NR	NR	NR	Insufficient warning properties; possible systemic effects at concentrations lower than those that produce irritation.
AEGL-2 (disabling)	0.10 ppm (0.41 mg/m ³)	0.10 ppm (0.41 mg/m ³)	0.083 ppm (0.34 mg/m ³)	0.053 ppm (0.21 mg/m ³)	0.026 ppm (0.11 mg/m ³)	One third of AEGL-3 values.
AEGL-3 (lethal)	0.31 ppm (1.3 mg/m ³)	0.31 ppm (1.3 mg/m ³)	0.25 ppm (1.0 mg/m ³)	0.16 ppm (0.65 mg/m ³)	0.078 ppm (0.32 mg/m ³)	No mortality in rats exposed at 14 ppm for 4 h (Pauluhn et al. 1990).

(Continued)

TABLE 7-1 Continued

Classification	10 min	30 min	1 h	4 h	8 h	End Point (Reference)
<i>Phenyl isocyanate</i> ^b						
AEGL-1 (non-disabling)	NR	NR	NR	NR	NR	Insufficient warning properties; possible systemic effects at concentrations lower than those that produce irritation.
AEGL-2 (disabling)	0.012 ppm (0.058 mg/m ³)	0.012 ppm (0.058 mg/m ³)	0.0096 ppm (0.047 mg/m ³)	0.0061 ppm (0.030 mg/m ³)	0.0030 ppm (0.015 mg/m ³)	One-third of AEGL-3 values.
AEGL-3 (lethal)	0.036 ppm (0.18 mg/m ³)	0.036 ppm (0.18 mg/m ³)	0.029 ppm (0.14 mg/m ³)	0.018 ppm (0.088 mg/m ³)	0.0091 ppm (0.044 mg/m ³)	4-h BMCL ₀₅ of 1.64 ppm in rats (Bayer AG 1991a)

^aWhen more than one of the monoisocyanates is detected at a scene, the lowest AEGL should be applied to the sum total concentration of all detected monoisocyanates because of a presumed common mode of action. On the basis of toxicity data on methyl isocyanate, it is plausible that exposure to these monoisocyanates might be associated with systemic toxicity at concentrations below those associated with irritation. Absence of AEGL-1 values does not imply that concentrations below AEGL-2 values are without effect.

^bPhenyl isocyanate has shown dermal sensitizing effects. Its respiratory sensitizing potential is unknown. Individuals who have a strong reaction might not be protected within the definition of effects for each AEGL level.

Abbreviations: BMCL₀₅, benchmark concentration, 95% confidence limit with a 5% response; MF, modifying factor; NR, not recommended; and UF, uncertainty factor.

TABLE 7-2 AEGL Values for Methyl Isocyanate and Toluene Diisocyanate

Classification	10 min	30 min	1 h	4 h	8 h
<i>Methyl isocyanate</i>					
AEGL-1 ^a (nondisabling)	NR	NR	NR	NR	NR
AEGL-2 (disabling)	0.40 ppm (0.94 mg/m ³)	0.13 ppm (0.32 mg/m ³)	0.067 ppm (0.16 mg/m ³)	0.017 ppm (0.034 mg/m ³)	0.0080 ppm (0.020 mg/m ³)
AEGL-3 (lethal)	1.2 ppm (2.8 mg/m ³)	0.40 ppm (0.95 mg/m ³)	0.20 ppm (0.47 mg/m ³)	0.050 ppm (0.12 mg/m ³)	0.025 ppm (0.060 mg/m ³)
<i>Toluene 2,4- and 2,6-diisocyanate</i>					
AEGL-1 (nondisabling)	0.02 ppm (0.14 mg/m ³)	0.02 ppm (0.14 mg/m ³)	0.02 ppm (0.14 mg/m ³)	0.01 ppm (0.07 mg/m ³)	0.01 ppm (0.07 mg/m ³)
AEGL-2 (disabling)	0.24 ppm (1.71 mg/m ³)	0.17 ppm (1.21 mg/m ³)	0.083 ppm (0.59 mg/m ³)	0.021 ppm (0.15 mg/m ³)	0.021 ppm (0.15 mg/m ³)
AEGL-3 (lethal)	0.65 ppm (4.63 mg/m ³)	0.65 ppm (4.63 mg/m ³)	0.51 ppm (3.63 mg/m ³)	0.32 ppm (2.28 mg/m ³)	0.16 ppm (1.14 mg/m ³)

^aInsufficient warning properties; possible systemic effects at concentrations lower than those that produce irritation. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 are without effect.

2. CONSIDERATIONS RELEVANT TO THE SELECTED MONOISOCYANATES

2.1. Absorption, Distribution, Metabolism, and Excretion

Metabolism and disposition data are not available for ethyl isocyanate, *n*-butyl isocyanate, cyclohexyl isocyanate, or phenyl isocyanate. Data on the distribution of the related compound methyl isocyanate are available. Tissue radioactivity levels in guinea pigs exposed to ¹⁴C-methyl isocyanate at 0.38-15.2 ppm for 1-6 h were proportional to the concentration-time product (Kennedy et al. 1993). Radioactivity was highest in the proximal airways but was detected throughout the entire nasal respiratory epithelial layer. In the tracheobronchial region and in the lung, the radioactivity accumulated in the subepithelial level extending to the terminal bronchiole, but was not detected in the alveolar region.

Isocyanates are known to form labile glutathione conjugates from which they may subsequently be released at a distal location (Zoltán and Klaassen 2001).

2.2. Mechanism of Toxicity

No studies that address the mechanism(s) of toxicity for ethyl isocyanate, *n*-butyl isocyanate, cyclohexyl isocyanate, or phenyl isocyanate are available. Because the toxicity of these monoisocyanates are clinically similar to that described for the structurally similar compound methyl isocyanate (respiratory tract irritation with delayed lethality), these compounds might share a similar mode of action.

TABLE 7-3 Chemical and Physical Data on Selected Monoisocyanates

Parameter	Ethyl Isocyanate	<i>n</i> -Butyl Isocyanate	Cyclohexyl Isocyanate	Phenyl Isocyanate
Synonyms	Isocyanatoethene; isocyanic acid, ethyl ester	1-Isocyanatobutane; isocyanic acid, butyl ester	Isocyanatocyclohexane isocyanic acid cyclohexyl ester	Isocyanatobenzene; carbamil; phenyl carbamide
CAS registry no.	109-90-0	111-36-4	3173-53-3	103-71-9
Chemical formula	C ₃ H ₅ NO	C ₃ H ₉ NO	C ₇ H ₁₁ NO	C ₇ H ₅ NO
Molecular weight	71.1	99.1	125.17	119.12
Physical state	Liquid	Liquid	Colorless liquid ^a	Liquid
Melting point	–	-75°C	–	-30°C
Boiling point	60°C	115°C	166°C ^a	158-168°C
Flash point	–	19°C (closed cup)	48°C (closed cup) ^b	55.5°C (open cup)
Density/specific gravity	0.9031 g/cm ³	0.88 g/cm ³ at 20°C	0.98 g/cm ³ at 25°C	1.0956 g/cm ³ at 20°C
Relative vapor density (air = 1)	2.45	3.0	4.3 ^b	–
Solubility in water	Insoluble	Slightly soluble	Decomposes ^a	Reacts violently ^c
Vapor pressure	200 mm Hg at 25°C	17.6 mm Hg at 25°C	94.6 mmHg at 20°C ^d	1.15 mm Hg at 20°C ^c
Conversion factors in air	1 ppm = 2.9 mg/m ³ 1 mg/m ³ = 0.34 ppm	1 ppm = 4.05 mg/m ³ 1 mg/m ³ = 0.25 ppm	1 ppm = 5.11 mg/m ³ 1 mg/m ³ = 0.196 ppm	1 ppm = 4.87 mg/m ³ 1 mg/m ³ = 0.21 ppm

Source: HSDB 2007a,b, 2012, 2013 except where noted; ^aEastman Kodak 1990; ^bIPCS 1997; ^cICI 1977; ^dSigma Aldrich 2012.

Results from human and animal studies indicate that methyl isocyanate is a severe irritant to mucous membranes. Ocular irritation was the most pronounced symptom reported in human experimental studies (Mellon Institute 1963, 1970; Kimmerle and Eben 1964). The most frequently reported symptoms in a population exposed to methyl isocyanate in Bhopal, India, were burning of the eyes, coughing, respiratory distress from pulmonary congestion, watering of the eyes, nausea, vomiting, muscle weakness, and central nervous system involvement secondary to hypoxia (Kamat et al. 1985; Lorin and Kulling 1986; Misra et al. 1987; Weill 1987; Andersson et al. 1988; Kamat et al. 1992). Human (Varma and Guest 1993) and animal (Fowler and Dodd 1986) fatalities are attributed to pulmonary edema.

Cyanide does not contribute significantly to the toxicity of methyl isocyanate. Cyanomethemoglobin was not found in the population exposed to methyl isocyanate in Bhopal (Misra et al. 1987), pulmonary lesions are not characteristic of cyanide intoxication (Weill 1987; Varma 1989), and standard thiosulfate/nitrite cyanide antidotes have not been successful in preventing deaths in animal studies (Nemery et al. 1985; Bucher et al. 1987; Varma et al. 1988). Finally, the time-to-death in humans and animals was not consistent with that associated with high dose cyanide intoxication (Varma and Guest 1993).

Developmental toxicity was observed in rodents after controlled exposure to methyl isocyanate. The mechanism of the systemic toxicity is unknown.

2.3. Structure-Activity Relationships

Data on the selected monoisocyanates are limited, so information on related compounds was also consulted. Toluene diisocyanate and methyl isocyanate have robust databases that include animal and human studies. The monoisocyanates reviewed in this chapter appear more similar to methyl isocyanate than 2,4- or 2,6-toluene diisocyanate with respect to lethality and respiratory irritation. Lethality benchmarks for the monoisocyanates are similar to those for methyl isocyanate; 4-h LC₅₀ values in rats were 4.6 ppm for phenyl isocyanate (Bayer AG 1991a), 18 ppm for *n*-butyl isocyanate (Bayer AG 1978), and 5-18 ppm for methyl isocyanate (NRC 2003). For toluene diisocyanate, 4-h LC₅₀ estimates for rats were 14-51 ppm (NRC 2004). In addition, deaths from toluene diisocyanate occur soon after exposure (within 36 h after a 1-h exposure in a rat study [Horspool and Doe 1977]), whereas deaths from the monoisocyanates, including methyl isocyanate, can occur as late as 30 days after exposure. Little respiratory-irritation data were available for comparison of the monoisocyanates. RD_{50s} (concentrations that reduce the respiratory rate by 50%) were estimated to be 1.3 ppm for mice exposed to methyl isocyanate for 90 min (Ferguson et al. 1986) and 2.7 ppm for rats exposed to phenyl isocyanate for 45 min

(Pauluhn et al. 1995). RD₅₀s for toluene diisocyanate were estimated to be 1.37-2.12 ppm in rats exposed for 3 h, 0.39 ppm in mice exposed for 1 h, and 0.8 ppm in mice exposed for 10 min (NRC 2004).

Differences exist in the sensitization potential, developmental effects, and systemic toxicity of methyl isocyanate and 2,4- or 2,6-toluene diisocyanate; however, no data are available to determine which of these structurally-related compounds is more representative of the selected monoisocyanates with respect to these end points. Karol and Kramarik (1996) noted that respiratory sensitization is a result of exposure to diisocyanates not monoisocyanates in the workplace. Toluene diisocyanate is a proven respiratory sensitizer in both human and laboratory animals (NRC 2004). Methyl isocyanate is not a respiratory sensitizer in animals (Mellon Institute 1970). No data on the sensitizing potential of ethyl isocyanate, *n*-butyl isocyanate, or cyclohexyl isocyanate were available. However, a mouse ear-swelling test indicated that phenyl isocyanate is a potent contact sensitizer in mice, stimulating both cellular and humoral immune responses (Karol and Kramarik 1996). Phenyl isocyanate was more potent than toluene diisocyanate in the ear-swelling test (Karol and Kramarik 1996). The potential for respiratory sensitization by phenyl isocyanate is not known.

Systemic effects have been well-documented after exposure to methyl isocyanate but not toluene diisocyanate. Methyl isocyanate produced fetal and neonatal deaths after inhalation exposure, but toluene diisocyanate did not. No inhalation data on the developmental toxicity of ethyl, *n*-butyl, cyclohexyl, or phenyl isocyanate in animals were available. In an oral exposure study, no evidence of developmental toxicity was observed in mice administered a single dose of phenyl isocyanate at 9.8 mg/kg (one-twentieth of the LD₅₀ [lethal dose, 50% lethality]) on gestation days 4, 7, 11, or 15 (Nehez et al. 1989). Cardiac arrhythmias have been reported in studies of methyl isocyanate but not in studies of toluene diisocyanate. For methyl isocyanate, systemic effects may occur at concentrations equal to or below those that cause irritation (NRC 2003).

In summary, the selected monoisocyanates exhibit toxic effects (respiratory irritation and delayed lethality) that are more similar to those associated with methyl isocyanate than with toluene diisocyanate. Differences exist in the sensitization potential, developmental effects, and systemic toxicity of methyl isocyanate and 2,4- or 2,6-toluene diisocyanate; however, the data are insufficient to determine which of these structurally-related compounds is more representative of the selected monoisocyanates with respect to these effects.

2.4. Species Differences

Toxicity data on ethyl isocyanate, *n*-butyl isocyanate, cyclohexyl isocyanate, and phenyl isocyanate in species other than the rat are lacking. Lethality data for the related compounds methyl isocyanate and toluene diisocyanate exhibit little species variability, as shown in Table 7-4.

TABLE 7-4 Lethality (LD₅₀s) of Methyl Isocyanate and Toluene Diisocyanate in Different Species

	1 h	2 h	3 h	4 h	6 h
<i>Methyl isocyanate (ppm)</i>					
Rat	41-45	21-27	–	5-18	6.1
Mouse	–	–	27	–	12
Guinea pig	–	–	27	11	5.4
<i>Toluene diisocyanate (ppm)</i>					
Rat	66	–	–	14-51	–
Mouse	–	–	–	9.7	–
Guinea pig	–	–	–	13	–
Rabbit	–	–	–	11	–

Sources: NRC 2003, 2004.

2.5. Concurrent Exposure Issues

Limited data comparing the toxicity of the four selected monoisocyanates with the well-studied compound methyl isocyanate suggest similarities in toxicity among the monoisocyanates that may reflect a common mode(s) of action. Thus, the lowest AEGL value for any of the detected monoisocyanates at an emergency scene should be applied to the sum total concentration of all monoisocyanates when multiple monoisocyanates are present.

2.6. Concentration-Exposure Duration Relationship

The relationship between concentration and duration of exposure with respect to lethality was examined by ten Berge et al. (1986) for approximately 20 irritant or systemically-acting vapors and gases. The investigators analyzed individual animal data sets by probit analysis, with exposure duration and exposure concentration as independent variables. An exponential function of $C^n \times t = k$, where the value of n ranged from 0.8 to 3.5 for different chemicals, was found to be an accurate quantitative descriptor for the chemicals evaluated. For methyl isocyanate, rat LC₅₀ data were used to estimate an empirical value for n of 1.0. However, data were inadequate to calculate an empirical value of n for the selected monoisocyanates in this chapter. Thus, default values of $n = 1$ for extrapolating from shorter to longer durations and $n = 3$ for extrapolating from longer to shorter durations were used.

2.7. Special Considerations

Some of the toxicity data on the four monoisocyanates in this chapter may have uncertainty with respect to exposure concentrations. One analysis (DuPont, unpublished material, 2008) showed that impinger/gas chromatography (GC) methods used to analyze *n*-butyl isocyanate underestimated concentrations when

compared with XAD-7 tube/high performance liquid chromatography (HPLC) analysis. In 1994, 20 air samples were collected side-by-side in various areas of a production facility using the impinger and XAD-7 tube sampling methods and subsequently analyzed using GC and HPLC methods, respectively. Comparison of the data showed that the XAD-7/HPLC method generally measured higher concentrations (two-fold higher on average) than the impinger/GC method; however, the magnitude of the difference was not consistent across the samples and the measurements were not always higher (see Table 7-5). A second analysis (Mobay 1978) reported that the Marcali colorimetric method underestimated concentrations of phenyl isocyanate (in a rat lethality study) when compared with HPLC analysis, and that the HPLC results were more consistent with the calculated concentrations. Information in the Mobay Corp. (1978) report was insufficient to allow an independent evaluation of the differences. Whether the analytic uncertainties also apply to ethyl isocyanate and cyclohexyl isocyanates is not known; however, studies of the latter two compounds were conducted in the 1960s and concentrations were calculated rather than measured. In light of the potential analytic uncertainties, information on the method used to analyze exposure concentrations is included in the descriptions of the toxicity data for the individual monoisocyanates presented later in this chapter.

TABLE 7-5 Comparison of *n*-Butyl Isocyanate Concentrations Obtained Using Impinger/GC and XAD-7 Tube/HPLC Methods

Impinger/GC (ppb)	XAD-7 Tube/HPLC (ppb)	Difference
1.3	9.4	623%
1.9	11.8	521%
2.5	10.5	320%
3.8	5	32%
4.4	9.4	114%
4.5	5.7	27%
5.2	7.1	37%
5.3	4.6	-13%
5.7	5.6	-2%
6.5	10	54%
6.6	9.6	45%
6.6	11	67%
8	11.6	45%
8.1	10.1	25%
8.3	9.1	10%
8.4	12.9	54%
10.7	21.3	99%
13.6	10.4	-24%
27	40.9	51%
32.4	24.5	-24%
Average percent difference		103%

Source: DuPont, unpublished material, 2008.

2.8. Data Adequacy and Research Needs

Some of the toxicity data on the four monoisocyanates in this chapter may have uncertainty with respect to exposure concentrations, as discussed in detail in Section 2.7. As will be discussed in subsequent sections, no data relevant to AEGL-1 or AEGL-2 end points in humans or animals exposed to ethyl isocyanate or cyclohexyl isocyanate were available. Toxicity data on ethyl isocyanate and cyclohexyl isocyanate are primarily from poorly-documented unpublished lethality studies that used small groups of rats. Thus, data on the well-studied, related compound—methyl isocyanate—were used to derive AEGL values for these two isocyanates. Additional research on the inhalation toxicity of ethyl isocyanate and cyclohexyl isocyanate might provide data suitable for the deriving chemical-specific AEGL values. Animal data were adequate to derive AEGL-3 values for *n*-butyl isocyanate and phenyl isocyanate; AEGL-2 values were derived from corresponding AEGL-3 values.

Methyl isocyanate is a developmental toxicant, and developmental effects were the basis for AEGL-2 and AEGL-3 values for this compound (NRC 2003). No inhalation data on the developmental toxicity of the four monoisocyanates in humans or animals were available. An oral study found no developmental toxicity in mice treated once with phenyl isocyanate at 9.8 mg/kg on gestation days 4, 7, 11, or 15 (Nehez et al. 1989). To account for the potential developmental toxicity of *n*-butyl isocyanate and phenyl isocyanate, a modifying factor was applied in the derivation of AEGL-2 and AEGL-3 values. Additional research on the developmental toxicity of these selected monoisocyanates might provide opportunities to refine the AEGL values for these compounds.

Of the two well-studied isocyanates, toluene diisocyanate is a known and potent respiratory sensitizer, whereas methyl isocyanate is not. The potential for respiratory sensitization induced by the four monoisocyanates is not known. However, phenyl isocyanate has been found to be a potent dermal sensitizer (Karol and Kramarik 1996). A cautionary note has been included in the AEGL tables for phenyl isocyanate to indicate that individuals who have a strong reaction might not be protected within the definition of effects for each AEGL level; this note is the same as used for the AEGL values for toluene diisocyanate (NRC 2004). Additional research on the potential respiratory sensitization of phenyl isocyanate would be beneficial.

3. ETHYL ISOCYANATE

3.1. Human Toxicity Data

No information regarding lethality, nonlethal toxicity, developmental toxicity, genotoxicity, or carcinogenicity in humans after acute inhalation exposure to ethyl isocyanate was available.

3.2. Animal Toxicity Data

3.2.1. Acute Lethality

Groups of three rats (strain and sex not specified) were exposed to ethyl isocyanate at 27 ppm for 6 h, 82 ppm for 6 h, or 506 ppm for 2 h and 50 min (Eastman Kodak 1964). Documentation of this study was limited to a summary table with few details. A known amount of liquid ethyl isocyanate was placed in a 6-cc test tube in a exposure chamber (24-24.5°C), and air was pumped into the chamber. Exposure concentrations were calculated from the amount of compound placed in the chamber and the chamber volume. Clinical signs in all the test groups were consistent with irritation. No deaths occurred in the 27-ppm group and all rats in the 82- and 506-ppm groups died within 24 h. Animals in the 27-ppm group were killed 14 days post-exposure; at necropsy, the lungs were reportedly hemorrhagic. Mortality and clinical data are summarized in Table 7-6.

3.2.2. Nonlethal Toxicity

No information on the nonlethal toxicity, developmental or reproductive toxicity, genotoxicity, or carcinogenicity of ethyl isocyanate in animals was available.

TABLE 7-6 Lethality and Clinical Findings in Rats Exposed to Ethyl Isocyanate

Calculated Concentration (ppm)	Duration	Mortality	Time of Death	Clinical Signs (time observed)
27	6 h	0/3	–	Blepharism, piloerection (1 min); lacrimation (15 min); dark eyes (1 h); nasal discharge (1 hr, 20 min).
82	6 h	3/3	Within 24 h (none during exposure)	Blepharism, piloerection, lacrimation (1 min). Gasping, dyspnea, dark eyes (20 min); ptyalism (55 min).
506	2 h, 50 min	3/3	2 h, 15 min; 2 h, 20 min; 2 h, 50 min	Blepharism, piloerection, lacrimation (immediately); ptyalism (1 min); gasping, dyspnea, dark eyes (5 min); nasal discharge (15 min); prostration (1 h, 35 min); convulsions (2 h, 15 min).

Source: Eastman Kodak 1964.

3.3. Data Analysis for AEGL-1 Values

3.3.1. Human Data Relevant to AEGL-1

No human data relevant to deriving AEGL-1 values for ethyl isocyanate were available.

3.3.2. Animal Data Relevant to AEGL-1

No animal data relevant to deriving AEGL-1 values for ethyl isocyanate were available.

3.3.3. Derivation of AEGL-1 Values

AEGL-1 values were not derived for ethyl isocyanate. The available data suggest that ethyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for ethyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

3.4. Data Analysis for AEGL-2 Values

3.4.1. Human Data Relevant to AEGL-2

No human data relevant to deriving AEGL-2 values for ethyl isocyanate were available.

3.4.2. Animal Data Relevant to AEGL-2

No animal data relevant to deriving AEGL-2 values for ethyl isocyanate were available. In the only available study, blepharism and lacrimation were observed in three rats exposed at 27 ppm for 6 h; that concentration was the only nonlethal exposure level examined (Eastman Kodak 1964).

3.4.3 Derivation of AEGL-2 Values

The toxicologic database on ethyl isocyanate was inadequate to derive AEGL-2 values. Therefore, AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that ethyl

isocyanate might be more toxic than methyl isocyanate. AEGL-2 values for ethyl isocyanate are presented in Table 7-7, and the calculations are presented in Appendix A.

3.5. Data Analysis for AEGL-3 Values

3.5.1. Human Data Relevant to AEGL-3

No human data relevant to deriving AEGL-3 values for ethyl isocyanate were available.

3.5.2. Animal Data Relevant to AEGL-3

Only one study on the acute lethality of ethyl isocyanate was available. Groups of three rats were exposed by inhalation to ethyl isocyanate at three concentrations for up to 6 h. All rats survived exposure at 27 ppm, whereas all animals died at 82 ppm and 506 ppm (Eastman Kodak 1964). Documentation of the study provided few details and concentrations were calculated rather than analytically confirmed.

3.5.3. Derivation of AEGL-3 Values

The toxicologic database on ethyl isocyanate was inadequate to derive AEGL-3 values. As discussed in Section 2.3 (Structure-Activity Relationships), ethyl isocyanate and the other three monoisocyanates considered in this chapter are structurally similar to and exert toxic effects comparable to methyl isocyanate. Therefore, AEGL-3 values were determined by using the AEGL-3 values established for the methyl isocyanate and dividing them by a modifying factor of 2 to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate. A comparison of the available lethality data on the two chemicals suggests that use of methyl isocyanate as a surrogate with a modifying factor of 2 to account for potentially higher toxicity results in sufficiently protective AEGL values. When groups of three rats were exposed to ethyl isocyanate for 6 h, all rats survived at 27 ppm and no rats survived at 82 ppm. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats (6/sex) was 6.1 ppm (NRC 2003). AEGL-3 values for ethyl isocyanate are presented in Table 7-8, and the calculations are presented in Appendix A.

TABLE 7-7 AEGL-2 Values for Ethyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.20 ppm	0.065 ppm	0.034 ppm	0.0085 ppm	0.0040 ppm
(0.58 mg/m ³)	(0.19 mg/m ³)	(0.099 mg/m ³)	(0.025 mg/m ³)	(0.012 mg/m ³)

TABLE 7-8 AEGL-3 Values for Ethyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.60 ppm (1.7 mg/m ³)	0.20 ppm (0.58 mg/m ³)	0.10 ppm (0.29 mg/m ³)	0.025 ppm (0.073 mg/m ³)	0.013 ppm (0.038 mg/m ³)

Consideration was also given to basing AEGL-3 values on the study of ethyl isocyanate conducted by Eastman Kodak (1964), in which 27 ppm caused no deaths in a group of three rats exposed for 6 h. If this approach is used, an interspecies uncertainty factor of 3 and an intraspecies uncertainty factor of 10 would be applied, as well as a modifying factor of 10 to account for the sparse database on ethyl isocyanate. Time scaling would be performed using the equation $C^n \times t = k$, with default values of $n = 3$ for extrapolating to shorter durations and $n = 1$ for extrapolating to longer durations. These calculations would result in AEGL-3 values of 0.30 ppm for 10 min, 0.21 ppm for 30 min, 0.16 ppm for 1 h, 0.10 ppm for 4 h, and 0.068 ppm for 8 h. However, this approach has greater uncertainty, particularly with respect to poor documentation of the study, small numbers of animals tested, and lack of analytic confirmation of the exposure concentrations (Eastman Kodak 1964).

3.6. Summary of AEGLs

3.6.1. AEGL Values and Toxicity End Points

AEGL-1 values are not recommended for ethyl isocyanate because of insufficient data and the potential for systemic effects to occur at concentrations below those associated with irritation. AEGL-2 and AEGL-3 values for ethyl isocyanate were estimated using the AEGL values established for methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate. AEGL values for ethyl isocyanate are presented in Table 7-9.

3.6.2. Other Standards and Guidelines

There are no other standards or guidelines for ethyl isocyanate.

4. CYCLOHEXYL ISOCYANATE

4.1. Human Toxicity Data

No information regarding the lethality, nonlethal toxicity, developmental toxicity, genotoxicity, or carcinogenicity in humans following acute inhalation exposure to cyclohexyl isocyanate was available.

TABLE 7-9 AEGL Values for Ethyl Isocyanate^a

Classification	10 min	30 min	1 h	4 h	8 h
AEGL-1 ^b (nondisabling)	NR	NR	NR	NR	NR
AEGL-2 (disabling)	0.20 ppm 0.58 mg/m ³	0.065 ppm (0.19 mg/m ³)	0.034 ppm (0.099 mg/m ³)	0.0085 ppm (0.025 mg/m ³)	0.0040 ppm (0.012 mg/m ³)
AEGL-3 (lethal)	0.60 ppm (1.7 mg/m ³)	0.20 ppm (0.58 mg/m ³)	0.10 ppm (0.29 mg/m ³)	0.025 ppm (0.073 mg/m ³)	0.013 ppm (0.038 mg/m ³)

^aWhen more than one of the monoisocyanates is detected at a scene, the lowest AEGL value should be applied to the sum total concentration of all detected monoisocyanates because of a presumed common mode of action for these chemicals.

^bNR, not recommended. On the basis of toxicity data on methyl isocyanate, it is plausible that exposure to ethyl isocyanate might be associated with systemic toxicity at concentrations below those associated with irritation. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

4.2. Animal Toxicity Data

4.2.1. Lethality

Groups of three rats (strain and sex not specified) were exposed to cyclohexyl isocyanate at 17.79, 53.2, or 1,017 ppm for up to 6 h (Eastman Kodak 1990, 1992). Documentation of the study, which was conducted in 1964 and submitted to the U.S. Environmental Protection Agency under the Toxic Substances Control Act Test Submission (Section 8D), consists of a tabular report. Chamber atmospheres were generated by passing air through a gas washing bottle or through a short open-end bubbler and diluting with clean air. The method for determining chamber concentrations was not specified, so whether the concentrations were calculated or measured is unknown. During exposure at 17.79 ppm, clinical signs of toxicity included blinking within 5 min, rough hair coat by 10 min, vasodilatation after 1 h and 25 min, lacrimation and accelerated respiration at 1 h and 55 min, and dyspnea in 4 h and 25 min. One rat died on day 7 post-exposure and the remaining animals were killed on day 8, presumably due to moribund condition. All of the treated animals had enlarged and spongy lungs that exhibited collapse and were consolidated by acute inflammatory exude; congestion of the kidneys and liver was also seen. At 53.2 ppm, clinical signs were similar, but appeared slightly earlier, and also included salivation at 3 h and 50 min and gasping in 4 h and 50 min. Two animals died in 6 h and the third rat died 12 days later. At 1,017 ppm, all rats died within 4 h and 10 min after exhibiting pronounced clinical signs.

Six male rats (strain not specified) were exposed whole-body to cyclohexyl isocyanate at an average chamber concentration of 1,401 ppm (Younger Laboratories 1974). Saturated vapors (generated by passing air through a 500-mL

flask containing 42.4 g of cyclohexyl isocyanate) were introduced into the chamber and the concentration was calculated from the amount of material vaporized. All animals died within 2.5 h after the start of exposure. Clinical signs of irritation were observed before death, and pulmonary hemorrhage was found at necropsy. In a similar experiment, four male and four female rats died within 2 h after the start of exposure to saturated vapor of cyclohexyl isocyanate generated in the same manner (Crawford and Anderson 1974); vapor concentrations were not estimated in this study.

Groups of five male and five female Wistar rats were exposed whole-body to saturated vapors of cyclohexyl isocyanate for 3 min, 10 min, or 1 h, followed by a 14-day observation period (Bayer AG 1980a). All rats exposed for 3 min survived until the end of the observation period; clinical signs of irritation were observed during exposure and persisted until 2 days post-exposure. Necropsy revealed speckled or dark red spots on the lungs in about 50% of the rats. Animals exposed for 10 min died within 11 days post-exposure; clinical signs of irritation and respiratory problems were observed. All rats died during the 1-h exposure. Necropsy of the animals that died in the 10-min and 1-h groups revealed enlarged lungs with dark red spots, fluid in the thoracic cavity, lobulated pattern of the liver, and bloated stomach. A summary of the acute lethality data from studies of rats exposed to cyclohexyl isocyanate are presented in Table 7-10.

TABLE 7-10 Acute Lethality in Rats Exposed to Cyclohexyl Isocyanate

Concentration (ppm)	Duration	Lethality	Clinical and Necropsy Findings	Reference
17.79	6 h	1/3 on day 7 2/3 killed on day 8	Irritation, lacrimation, dyspnea, inflammation in lungs, congestion of kidney and liver.	Eastman Kodak 1990, 1992
53.2	6 h	2/3 during exposure 1/3 on day 12	Same effects as the 17.79-ppm group, plus salivation, and gasping.	
1,017	4 h	3/3 after 4 h	Same effects as the 53.2-ppm group, but more severe.	
1,401	1-2.5 h	6/6	Irritation, hemorrhage in lungs.	Younger Laboratories 1974
Saturated	2 h	8/8	None reported.	Crawford and Anderson 1974
	3 min	0/10	Irritation, dark spots on lungs.	Bayer AG 1980a
	10 min	10/10 within 11 days	Respiratory problems, enlarged lungs with red spots, fluid, lobulated liver.	
	1 h	10/10 during exposure	Same effects as the 10-min group.	

4.2.2. Nonlethal Toxicity

No information on the nonlethal toxicity, developmental or reproductive toxicity, genotoxicity, or carcinogenicity of cyclohexyl isocyanate in animals was found.

4.3. Data Analysis for AEGL-1 Values

4.3.1. Human Data Relevant to AEGL-1

No human data relevant to calculating AEGL-1 values for cyclohexyl isocyanate were available.

4.3.2. Animal Data Relevant to AEGL-1

No animal data relevant to calculating AEGL-1 values for cyclohexyl isocyanate were available.

4.3.3. Derivation of AEGL-1 Values

AEGL-1 values were not derived for cyclohexyl isocyanate. The available data suggest that cyclohexyl isocyanate and the three other selected monoisocyanates considered in this chapter exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for cyclohexyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

4.4. Data Analysis for AEGL-2 Values

4.4.1. Human Data Relevant to AEGL-2

No human data relevant to calculating AEGL-2 values for cyclohexyl isocyanate were available.

4.4.2. Animal Data Relevant to AEGL-2

No animal data relevant to calculating AEGL-2 values for cyclohexyl isocyanate were available. All of the concentrations of cyclohexyl isocyanate tested were associated with 100% mortality (Crawford and Anderson 1974; Younger Laboratories 1974; Bayer AG 1980a; Eastman Kodak 1990, 1992).

4.4.3. Derivation of AEGL-2 Values

The toxicologic database for cyclohexyl isocyanate was inadequate to derive AEGL-2 values. AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate and dividing them by a modifying factor of 2 to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate. AEGL-2 values for cyclohexyl isocyanate are presented in Table 7-11, and the calculations are provided in Appendix A.

4.5. Data Analysis for AEGL-3 Values

4.5.1. Human Data Relevant to AEGL-3

No human data relevant to calculating AEGL-3 values for cyclohexyl isocyanate were available.

4.5.2. Animal Data Relevant to AEGL-3

All of the studies on cyclohexyl isocyanate were conducted in rats, and all of the test concentrations resulted in 100% mortality (Crawford and Anderson 1974; Younger Laboratories 1974; Bayer AG 1980a; Eastman Kodak 1990, 1992). The lowest concentrations of cyclohexyl isocyanate tested in these studies were 17.79 ppm for 6 h, 1,017 ppm for 4 h, and 1,401 ppm for 2.5 h or less.

4.5.3. Derivation of AEGL-3 Values

The toxicologic database for cyclohexyl isocyanate was inadequate to derive AEGL-3 values. AEGL-3 values were determined by using the AEGL-3 values established for the related compound methyl isocyanate and dividing them by a modifying factor of 2 to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate. A comparison of the available lethality data on the two chemicals suggests that this approach results in sufficiently protective AEGL values. When three rats were exposed to cyclohexyl isocyanate at 18 ppm for 6 h, one died on day 7 post-exposure and the other two were killed on day 8, presumably because of moribund condition. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats is 6.1 ppm (NRC 2003). AEGL-3 values for cyclohexyl isocyanate are presented in Table 7-12, and the calculations are provided in Appendix A.

TABLE 7-11 AEGL-2 Values for Cyclohexyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.20 ppm (1.0 mg/m ³)	0.065 ppm (0.33 mg/m ³)	0.034 ppm (0.17 mg/m ³)	0.0085 ppm (0.043 mg/m ³)	0.0040 ppm (0.020 mg/m ³)

TABLE 7-12 AEGL-3 Values for Cyclohexyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.60 ppm (3.1 mg/m ³)	0.20 ppm (1.0 mg/m ³)	0.10 ppm (0.51 mg/m ³)	0.025 ppm (0.13 mg/m ³)	0.013 ppm (0.066 mg/m ³)

4.6. Summary of AEGLs

4.6.1. AEGL Values and Toxicity End Points

AEGL-1 values are not recommended for cyclohexyl isocyanate because of insufficient data and because of the potential for systemic effects to occur at concentrations below those associated with irritation. AEGL-2 and AEGL-3 values for cyclohexyl isocyanate were estimated from those established for methyl isocyanate and dividing them by a modifying factor of 2 to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate. AEGL values for cyclohexyl isocyanate are presented in Table 7-13.

4.6.2. Other Standards and Guidelines

There are no other standards or guidelines for cyclohexyl isocyanate.

5. *n*-BUTYL ISOCYANATE

5.1. Human Toxicity Data

5.1.1. Acute Lethality

No information regarding lethality in humans after acute inhalation exposure to *n*-butyl isocyanate was available.

5.1.2. Nonlethal Toxicity

An industrial hygiene survey conducted at a facility using *n*-butyl isocyanate as a chemical intermediate reported that exposure to *n*-butyl isocyanate at a concentration of 5-10 ppb (0.005-0.01 ppm) resulted in “noticeable” ocular irritation, and that normal work operations were not possible at 50 ppb (0.05 ppm) (Haskell Laboratory 1989). The report included an opinion that exposure to *n*-butyl isocyanate at 50 ppb (0.05 ppm) was not expected to impair ability to escape, but did not provide any supporting details. Concentrations of *n*-butyl isocyanate were measured using an impinger/gas chromatograph (GC) method. A later report compared measurements using this method with those obtained from XAD-7 tube/HPLC (DuPont, unpublished material, 2008), and found that the

impinger/GC method underestimated *n*-butyl isocyanate concentrations by 40-400%. Analysis of those data indicates that, when averaged across all of the samples, the XAD-7 tube/HPLC method gave results that were two-fold higher than the impinger/GC method (see Table 7-5).

DuPont (unpublished material, 2008) also reported the findings of two industrial hygiene surveys. In one assessment, subjective responses regarding ocular irritation and lacrimation were obtained from five workers who were not required to wear respirators. Data collected from the workers' personal air samplers indicated that "personnel did not experience eye irritation/lacrimation up to 52.8 ppb over a 7- to 8-h sample" (measured concentrations were 12.9-52.8 ppb [0.013-0.053 ppm]). In the second assessment, air monitoring data were assessed in conjunction with daily logs recording reports of ocular irritation or lacrimation by persons not wearing respirators. This assessment concluded that "personnel without respiratory protection were not experiencing eye irritation when air sample results indicated airborne butyl isocyanate levels ranging from 8 to 40 ppb" (DuPont, unpublished material, 2008). Neither survey was sufficiently rigorous to be used as a basis for deriving AEGL values.

5.1.3. Developmental and Reproductive Effects, Genotoxicity, and Carcinogenicity

No information regarding the developmental or reproductive toxicity, genotoxicity, or carcinogenicity of *n*-butyl isocyanate in humans was available.

TABLE 7-13 AEGL Values for Cyclohexyl Isocyanate^a

Classification	10 min	30 min	1 h	4 h	8 h
AEGL-1 ^b (nondisabling)	NR	NR	NR	NR	NR
AEGL-2 (disabling)	0.20 ppm (1.0 mg/m ³)	0.065 ppm (0.33 mg/m ³)	0.034 ppm (0.17 mg/m ³)	0.0085 ppm (0.043 mg/m ³)	0.0040 ppm (0.020 mg/m ³)
AEGL-3 (lethal)	0.60 ppm (3.1 mg/m ³)	0.20 ppm (1.0 mg/m ³)	0.10 ppm (0.51 mg/m ³)	0.025 ppm (0.13 mg/m ³)	0.013 ppm (0.066 mg/m ³)

^aWhen more than one of the monoisocyanates is detected at a scene, the lowest AEGL value should be applied to the sum total concentration of all detected monoisocyanates due to presumed common mode of action for these chemicals.

^bNR, not recommended. On the basis of toxicity data on methyl isocyanate, it is plausible that exposure to cyclohexyl isocyanate might be associated with systemic toxicity at concentrations below those associated with irritation. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

5.2. Animal Toxicity Data

5.2.1. Acute Lethality

In experiments conducted by Younger Laboratories for Monsanto Chemical Company (Younger Laboratories 1956), groups of three male rats died 10-15 min after being exposed to an unspecified concentration of *n*-butyl isocyanate (described only as “considerably less than saturated”). Another group of three rats exposed to “relatively low” concentrations died after 45, 60, and 75 min. All rats exhibited signs of irritation and respiratory distress immediately after exposure began. Necropsy revealed severe edema in the nasal passages and pulmonary congestion.

Mobay Chemical Company (1961) conducted experiments in which groups of six rats were exposed to a saturated vapor of *n*-butyl isocyanate (about 22,000 ppm). Although the experimental protocol specified a 6-h exposure, results showed that all six rats died within 10-15 min. No further details of the experiments were provided.

The acute inhalation toxicity of *n*-butyl isocyanate in groups of six male Spartan Sprague-Dawley rats (200-300 g) was reported by IRDC (1965). Rats were exposed to *n*-butyl isocyanate at 5.5, 7.9, 10.9, 12.0, 18.9, 21.7, 27.9, 28.2, or 34.6 mg/m³ (1.4, 1.9, 2.7, 3.0, 4.7, 5.4, 7.0, 7.1, and 8.7 ppm) for 1 h in a 9-L, airtight chamber, and were subsequently observed for 14 days. *n*-Butyl isocyanate vapor was generated by heating the compound in a U-tube submerged in a water bath, and the resulting vapor was passed through glass wool filters and calcium chloride drying tubes. Concentrations were adjusted by varying the infusion rate into the U-tube. Samples of the chamber atmosphere were analyzed spectrophotometrically and compared to a pre-established standard curve. Clinical signs of toxicity in rats exposed to *n*-butyl isocyanate increased with concentration and included hypoactivity, increased grooming and escape behavior during exposure, salivation, lacrimation, dyspnea, and death. Group-specific mortality incidences and necropsy findings are presented in Table 7-14. Although no deaths occurred at 12.0 mg/m³ (3.0 ppm), deaths in the groups exposed at 7.9 and 10.9 mg/m³ (1.9 and 2.7 ppm, respectively) suggest that the absence of mortality in the 12-mg/m³ group was probably a function of the small group size. The investigators calculated a 1-h LC₅₀ of 15.2 mg/m³ (95% CI: 12.1-19.0 mg/m³), equivalent to 3.8 ppm, using the method of Litchfield and Wilcoxon (1949). As shown in Table 7-14, lethality was often delayed.

A lethality assay using groups of six male ChR-CD rats exposed to *n*-butyl isocyanate (purity not specified) for 4 h was conducted by DuPont (Haskell Laboratory 1968). Concentrations of 12.5, 17.5, 22, 31.5, and 33.5 ppm were measured by impinger/GC analysis. Vapor was generated by metering *n*-butyl isocyanate into a heated (125-150°C) stainless steel T-tube. Vapor was then carried via measured air flow to a 16-L bell jar containing the rats. Rats exhibited irregular breathing, hyperemia, gasping, pale ears, and lacrimation during exposure. Post-exposure observations included 10-20% loss of body weight during

the first day; respiratory distress characterized by gasping, labored breathing, congestion, and rales; red discharge from the eyes; and priapism. Lethality findings are presented in Table 7-15. Some deaths occurred during the 30-day observation period at all test concentrations. Body weight loss and signs of respiratory distress were observed throughout the post-exposure period. Death occurred during exposure only at the two highest concentrations. Pathology findings included dark red-colored, edematous lungs, necrosis and desquamation of respiratory epithelium, and signs of increased capillary permeability. Surviving rats exhibited regeneration of the bronchial epithelium and proliferation of connective tissue resulting in fibrotic changes and atelectasis. Bronchopneumonia was evident in many rats by post-exposure day 14. A 4-h LC₅₀ of 15.6 ppm (95% CI: 13.3-18.2 ppm) was reported.

TABLE 7-14 Lethality in Rats After Exposure to n-Butyl Isocyanate Vapor for 1 Hour

Concentration ^a (mg/m ³) [ppm]	Lethality	Comments and Necropsy Findings
5.5 mg/m ³ (1.4 ppm)	0/6	No gross lesions in four rats; two had 8-mm areas of congestion or hemorrhage in lungs.
7.9 mg/m ³ (1.9 ppm)	1/6	Death on post-exposure day 1; rat had hemorrhagic lungs. All survivors had inflated lungs and involuted thymus; four had mucus in trachea and bronchi; two had lungs with dark areas or areas of consolidation; one had gastric edema and hemorrhage.
10.9 mg/m ³ (2.7 ppm)	2/6	Deaths on post-exposure days 9 and 13. Survivors had inflated lungs, and three had involuted thymus and fluid in small intestine.
12.0 mg/m ³ (3.0 ppm)	0/6	All rats had inflated lungs; two had pulmonary consolidation; one had pulmonary congestion; one had lungs with dark areas; one had pulmonary hyperemia; one had mucus in the trachea.
18.9 mg/m ³ (4.7 ppm)	6/6	Five deaths on post-exposure day 2, one death on post-exposure day 13. No necropsy findings reported.
21.7 mg/m ³ (5.4 ppm)	4/6	Two deaths on post-exposure day 2, one death each on days 9 and 11. Survivors had lungs with dark foci/consolidation, fluid in gastrointestinal tract.
27.9 mg/m ³ (7.0 ppm)	6/6	Two deaths on day of exposure, four deaths on post-exposure day 1.
28.2 mg/m ³ (7.1 ppm)	6/6	One death on day of exposure, five deaths on post-exposure day 1.
34.6 mg/m ³ (8.7 ppm)	6/6	All deaths on day of exposure.

^aMeasured spectrophotometrically.
Source: IRDC 1965.

TABLE 7-15 Lethality in Male Rats Exposed to *n*-Butyl Isocyanate for 4 Hours

Concentration ^a (ppm)	Mortality		
	During Exposure	14-Days Post-Exposure	30-Days Post-Exposure
12.5	0/6	0/6	2/6
17.5	0/6	2/6	3/6
22	0/6	2/6	5/6
31.5	2/6	6/6	6/6
53.5	2/6	6/6	6/6

^aMeasured by impinger/GC.

Source: Haskell Laboratory 1968.

A series of studies on *n*-butyl isocyanate were conducted by Bayer AG Institute for Toxicology for Miles, Inc. (Bayer AG 1978), which submitted the reports (in German) to EPA's toxic substances control act test submissions (TSCATS Section 8E) database. The studies included: 1- and 4-h lethality experiments in rats; another 1-h lethality study in rats; a study of cholinesterase activity in rats exposed to a lethal concentration; and a study of nonlethal effects in rats exposed for 4 h. The study of nonlethal effects was published by Pauluhn et al. (1990), and is described in Section 5.2.2.1. Salient portions of the acute lethality studies were translated to describe the other studies. In a 1-h inhalation study, groups of five male and five female Wistar rats were exposed to *n*-butyl isocyanate at 156, 520, or 978 mg/m³. Vapors were generated at room temperature and distributed through the chamber with a fan, and were analyzed by flame ionization detection (FID). Mortality incidences were recorded 14 days post-exposure (see Table 7-16). A 1-h LC₅₀ of 425 mg/m³ (95% CI: 280-646 mg/m³) or its equivalent of 105 ppm (95% CI: 70-162 ppm) was reported for males and females. Labored breathing was apparent as soon as exposure was initiated at all concentrations. During the post-exposure period, animals exhibited dull and unkempt coat, stiff gait, tearing, and labored breathing. Areas of the ocular and nasal mucosa were reddened and swollen. In the 4-h lethality study, groups of five male rats were exposed to *n*-butyl isocyanate at 90 or 285 mg/m³ (22 or 70 ppm) and groups of five female rats were exposed at 90, 285, or 469 mg/m³ (22, 70, and 116 ppm) (Bayer AG 1978). Mortality data from this study are presented in Table 7-16. A 4-h LC₅₀ of 80 mg/m³ (18 ppm) was reported for female rats; the 4-h LC₅₀ for males was less than 90 mg/m³ (22.5 ppm). Clinical observations were observed in all groups and were consistent with those reported in the 1-h study.

In a second 1-h inhalation study, groups of five male and five female Wistar rats were exposed to *n*-butyl isocyanate at 375, 887, or 932 mg/m³ (94, 222, and 233 ppm), and followed for 28 days (Bayer AG 1978). The experimental design prevented dermal contact with the vapor, although details of the apparatus were not provided. Concentrations were analyzed by FID. Mortality incidences were

recorded at 28 days post-exposure (see Table 7-16). The 1-h LC₅₀ values estimated for male and female rats were 500 mg/m³ (125 ppm) and 600 mg/m³ (150 ppm), respectively. Animals in all the exposure groups exhibited labored breathing, and sedation was observed in some. Mucosal irritation was observed. Necropsy findings included pulmonary edema, emphysema, and “spotty changes”; pale liver and spleen; lobular appearance of the liver; and distended stomach and intestines.

Lethality benchmarks for *n*-butyl isocyanate are presented in Table 7-17.

5.2.2. Nonlethal Toxicity

5.2.2.1. Rats

IRDC (1965) exposed groups of six rats to *n*-butyl isocyanate at concentrations of 5.5, 7.9, 10.9, 12.0, 18.9, 21.7, 27.9, 28.2, or 34.6 mg/m³ for 1 h. Clinical signs included hypoactivity, increased grooming (during exposure), escape behavior (during exposure), salivation, lacrimation, and dyspnea. Although these responses were reportedly related to concentration, it was unclear which (if any) were associated with the nonlethal exposures. Deaths occurred in all but the 5.5 mg/m³-ppm and 12.0 mg/m³-groups (see Section 5.2.1).

TABLE 7-16 Lethality in Rats Exposed to *n*-Butyl Isocyanate for 1 or 4 Hours

Concentration	Lethality	Time of Death
1-h, 14-day follow-up		
156 mg/m ³ (39 ppm)	0/5 (males) 0/5 (females)	
520 mg/m ³ (130 ppm)	3/5 (males) 4/5 (females)	8-14 days post-exposure 9-13 days post-exposure
978 mg/m ³ (245 ppm)	5/5 (males) 5/5 (females)	1-3 days post-exposure 1 h to 12 days post-exposure
1-h, 28-day follow-up		
375 mg/m ³ (94 ppm)	1/10 (males) 2/10 (females)	10 days post-exposure 12 and 21 days post-exposure
887 mg/m ³ (222 ppm)	10/10 (males) 9/10 (females)	8 h to 24 days post-exposure 4-16 days post-exposure
932 mg/m ³ (233 ppm)	10/10 (males) 10/10 (females)	6 h to 12 days post-exposure 2-22 days post-exposure
4-h, 14-day follow-up		
90 mg/m ³ (22 ppm)	4/5 (males) 3/5 (females)	7-10 days post-exposure 11-12 days post-exposure
285 mg/m ³ (70 ppm)	5/5 (males) 4/5 (females)	1 h to 8 days post-exposure 9-14 days post-exposure
469 mg/m ³ (116 ppm)	5/5 (females)	2 h to 4 days post-exposure

^aMeasured by flame ionization detection.

Source: Bayer AG 1978.

TABLE 7-17 Lethality Benchmarks for *n*-Butyl Isocyanate

Study (analytic method)	Lethality Benchmark	Comments
IRDC 1965 (spectrophotometry)	1-h LC ₅₀ : 3.8 ppm	Deaths delayed 1-13 days
Haskell Laboratory 1968 (impinger/GC)	4-h LC ₅₀ : 15.6 ppm	Post-exposure deaths; time to death was a function of concentration.
Bayer AG 1978 (FID)	1-h LC ₅₀ : 105 ppm (males and females)	Followed for 14 days
	1-h LC ₅₀ : ~125 ppm (males)	Followed for 28 days
	1-h LC ₅₀ : ~150 ppm (females)	Followed for 28 days
	4-h LC ₅₀ : <22.5 ppm (males)	Followed for 14 days
	4-h LC ₅₀ : ≈18 ppm (females)	Followed for 14 days

Pulmonary function, arterial blood gases, acid-base status, and bronchioalveolar lavage fluid (BALF) composition were analyzed in groups of 20 male Wistar rats (WISW SPF-Cpb; 9-12 weeks old) exposed to *n*-butyl isocyanate (technical grade, 99.5%) at target concentrations of 0, 8, 25, or 50 mg/m³ for 4 h (Pauluhn et al. 1990). Analytic concentrations of 7.6, 23.5, and 55.2 mg/m³ (equivalent to 1.9, 5.9, and 14 ppm) were determined by HPLC analysis of three samples (sampling rate of 0.5 L/min). The animals were exposed using a head-nose only dynamic method that prevented mixing of the test atmosphere with exhaled air and also prevented hydrolytic degradation and aerosol formation. Rats exposed to *n*-butyl isocyanate at 7.6 mg/m³ exhibited only transient clinical signs (hypothermia, bradypnea, and mucous membrane irritation) during the first day. In the 23.5- and 55.2-mg/m³ groups, signs of severe respiratory distress were observed that resolved within 1 week in the 23.5-mg/m³ group but persisted through the 4-week observation period in the 55.2-mg/m³ group. At the highest concentration, decreased body temperature (data not provided in report) was detected 10-min post-exposure. Observations at 4 weeks post-exposure included minor (but statistically insignificant relative to controls) changes in some pulmonary function parameters, significantly decreased arterial oxygen, increased arterioalveolar oxygen difference, and significantly increased blood proteins, lactate dehydrogenase (LDH) activity levels, and relative lung weight. Histopathologic examinations of the lungs revealed the greatest effect in rats exposed at the highest concentration, which included gross findings of consolidation, distention, hemorrhagic areas, edema, and pleural effusions. Microscopic changes included increased numbers of alveolar macrophages, perivascular round-cell infiltration, focal fibroproliferative reactions, emphysema, thickening of the septa, and pneumonia in rats exposed at 23.5 mg/m³ or higher; the effects were described as occurring “marginally” in the 23.5-mg/m³ group. In summary, a 4-h exposure of male rats to *n*-butyl isocyanate at 7.6 mg/m³ produced minor transi-

ent clinical effects that fully resolved within 24 h. More notable effects were observed at 23.5 mg/m³, which resolved within 1 week, and persistent clinical effects and notable histopathologic findings consistent with significant pulmonary injury were found at 55.2 mg/m³.

5.2.2.2. Guinea Pigs

Tests of *n*-butyl isocyanate-bovine serum albumin conjugate in groups of four male Hartley guinea pigs induced only a weak, transient response (Haskell Laboratory 1982). The experiments involved multiple head-only exposures for 10-min/day, 5 days/week until a positive respiratory response occurred. During exposure, guinea pigs were placed in Lucite[®] body plethysmographs which were connected to an air pressure transducer to assess changes in respiratory rate. Three guinea pigs developed a positive response to *n*-butyl isocyanate after 2 weeks but the response was transient and of insufficient duration to allow for assessing the response to a challenge with other isocyanates. The concentration of *n*-butyl isocyanate-bovine serum albumin conjugate that generated the transient response was not specified.

5.2.3. Repeated Exposure

In a lung function study, groups of 20 male Wistar rats were exposed (head-nose only) to *n*-butyl isocyanate vapors at target concentrations of 0 (conditioned air), 1, 5, 15, or 25 mg/m³ (0, 0.25, 1.25, 3.75, 6.25 ppm) for 6 h/day for 5 days, and were observed for 5 weeks (Pauluhn and Eben 1991). Analytic concentrations of 0, 1.09, 6.22, 14.67, and 25.97 mg/m³ (0, 0.27, 1.55, 3.67, and 6.49 ppm) were determined by HPLC analysis of nitro-reagent reaction product. Twelve rats in the 25 mg/m³-group died 2 weeks after exposure; no deaths occurred in the other groups. No clinical signs of toxicity were observed in rats of the 1- or 5 mg/m³-groups. At 15 and 26 mg/m³, rats exhibited unkempt appearance, labored breathing, reduced motility, hypothermia, and serous nasal discharge. Overall evaluation of lung function revealed no significant differences in the 1-mg/m³ group compared with the control group. Rats in the 15-mg/m³ group exhibited some effects (BALF composition) that were marginally different from controls. On the basis of clinical signs, pulmonary function test results, and BALF analysis, the investigators concluded that delayed lethality was the result of obstructive and progressive lung damage with associated severe disturbance of ventilatory perfusion.

5.2.4. Developmental and Reproductive Effects

No information on the developmental or reproductive toxicity of *n*-butyl isocyanate vapor in animals was available.

5.2.5. Genotoxicity

n-Butyl isocyanate was not mutagenic in *Salmonella typhimurium* strains TA 1535, TA 1537, TA 98, or TA 100 with or without metabolic activation (OECD 2005). In the mouse lymphoma assay, *n*-butyl isocyanate was genotoxic only in the absence of metabolic activation, but it was not determined if this was the result of gene mutation or chromosomal aberrations (OECD 2005). No *in vivo* genotoxicity data were available.

5.2.6. Carcinogenicity

No information on the carcinogenicity of *n*-butyl isocyanate vapor in animals was available.

5.3. Data Analysis for AEGL-1

5.3.1. Human Data Relevant to AEGL-1

Data relevant to AEGL-1 effects in humans are limited to industrial hygiene reports noting that exposure to *n*-butyl isocyanate at concentrations as high as 40-50 ppb (0.040-0.050 ppm) did not cause ocular irritation in workers (Haskell Laboratory 1989; DuPont, unpublished material, 2008). However, the reports were not sufficiently rigorous or well documented to form the basis of AEGL-1 values for *n*-butyl isocyanate.

5.3.2. Animal Data Relevant to AEGL-1

Reliable exposure-response data for AEGL-1 severity effects in animals were not available for *n*-butyl isocyanate. Signs of irritation and respiratory distress were observed in surviving rats in lethality studies, but the severity of the nonlethal effects was not specified.

5.3.3. Derivation of AEGL-1 Values

AEGL-1 values were not derived for *n*-butyl isocyanate or any of the other three selected monoisocyanates. The available data suggest that *n*-butyl isocyanate and the other monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for *n*-butyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

5.4. Data Analysis for AEGL-2

5.4.1. Human Data Relevant to AEGL-2

The industrial hygiene report of DuPont (Haskell Laboratory 1989) provided the only information on *n*-butyl isocyanate relevant to AEGL-2 effects in humans. The report stated that exposure to *n*-butyl isocyanate at 50 ppb (0.05 ppm) for an unspecified duration was considered incompatible with normal work operations, but would not impair escape. However, no details of exposure estimates or health evaluations were provided; thus, the data were considered unsuitable for deriving AEGL-2 values.

5.4.2. Animal Data Relevant to AEGL-2

A single 4-h exposure of rats to *n*-butyl isocyanate at a concentration 23.5 mg/m³ (5.9 ppm) resulted in signs of severe respiratory distress which resolved within 1 week, whereas exposure at 55.2 mg/m³ (14 ppm) resulted in persistent clinical effects (Pauluhn et al. 1990). Histopathologic findings at 55.2 mg/m³ were consistent with significant pulmonary injury; “marginal” pulmonary histopathologic findings were reported at 23.5 mg/m³, but details of the incidence and severity of effects were not provided (Pauluhn et al. 1990); thus, it is difficult to evaluate whether the findings were consistent with AEGL-2 effects.

In a repeated exposure study, rats exposed to *n*-butyl isocyanate at 15 mg/m³ (3.8 ppm) for 6 h/day for 5 consecutive days had minor changes in BALF composition but no significant histopathologic findings; in rats similarly exposed at 25 mg/m³ (6.3 ppm), 60% mortality (12/20) occurred during post-exposure week 2 (Pauluhn and Eben 1991).

5.4.3. Derivation of AEGL-2 Values

The available human data and single-exposure animal toxicity data were inadequate for deriving AEGL-2 values for *n*-butyl isocyanate. Therefore, AEGL-2 values were determined by adjusting the AEGL-3 values for *n*-butyl isocyanate; each of the corresponding AEGL values was divided by 3. This approach is justified by the steep concentration-response curve observed in a mortality study; no rats died after a 1-h exposure at 39 ppm, and 70% (7/10) died at 130 ppm (Bayer AG 1978). AEGL-2 values for *n*-butyl isocyanate are presented in Table 7-18, and their derivation is presented Appendix A.

TABLE 7-18 AEGL-2 Values for *n*-Butyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.10 ppm (0.41 mg/m ³)	0.10 ppm (0.41 mg/m ³)	0.083 ppm (0.34 mg/m ³)	0.053 ppm (0.21 mg/m ³)	0.026 ppm (0.11 mg/m ³)

For comparison, consideration was given to possible AEGL-2 values based on the repeated-exposure study of Pauluhn and Eben (1991). The no-effect level relevant to AEGL-2 values in that study was 3.8 ppm; only minor changes in BALF composition were observed. If 3.8 ppm is used as the point of departure (assuming a 6 h duration), AEGL-2 values could be calculated by applying a total uncertainty factor of 30 (3 for interspecies differences and 10 for intraspecies variability), applying a modifying factor of 3 (to account for potential developmental toxicity of *n*-butyl isocyanate based on data for the related compound methyl isocyanate), and performing time scaling with the equation $C^n \times t = k$ (using default values of $n = 3$ for extrapolation to shorter durations and $n = 1$ for extrapolation to longer durations). The resulting AEGL-2 values would be 0.097, 0.097, 0.077, 0.048, and 0.032 ppm for 10-min, 30-min, 1-h, 4-h, and 8-h durations, respectively. These values are consistent with those obtained by adjusting the AEGL-3 values.

5.5. Data Analysis for AEGL-3

5.5.1. Human Data Relevant to AEGL-3

No data on lethality in humans exposed to *n*-butyl isocyanate vapor were available.

5.5.2. Animal Data Relevant to AEGL-3

Lethality data on inhalation exposure to *n*-butyl isocyanate are only available for rats exposed for 1 or 4 h (IRDC 1965; Haskell Laboratory 1968; Bayer AG 1978); lethality benchmarks from these studies are presented in Table 7-17. In addition to lethality studies, a pulmonary function study (Pauluhn et al. 1990) identified a nonlethal concentration of 14 ppm for a 4-h exposure. Table 7-19 compares these studies. The 1-h studies identified divergent LC_{50} and nonlethal concentrations, despite using similar group sizes. Likewise, the 4-h studies also had inconsistent results; 14 ppm was not lethal to male rats in the study by Pauluhn et al. (1990), whereas LC_{50} values of 15.6 and about 20 ppm were identified in the studies by DuPont (Haskell Laboratory 1968) and Miles, Inc. (Bayer AG 1978).

The Pauluhn et al. (1990) study was selected as the basis for deriving AEGL-3 values. The study was the only one to use HPLC analysis, a method that appears to be more reliable than either spectrophotometric methods or GC analysis. Furthermore, the study was published, and used large group sizes (20 per exposure).

5.5.3. Derivation of AEGL-3 Values

The highest nonlethal concentration of 14 ppm in the 4-h rat study by Pauluhn et al. (1990) was selected as the point of departure for deriving AEGL-3 values. That study tested a larger number of rats and used a more reliable analytic

technique (HPLC analysis) for measuring exposure concentrations than other studies. An interspecies uncertainty factor of 3 was applied on the basis of LC₅₀ data on the related compound methyl isocyanate, which showed relatively little interspecies differences (about a 2-fold difference in 6-h LC₅₀s among rats, mice, and guinea pigs; see Section 2.4). An intraspecies uncertainty factor was 10 was also applied. Both uncertainty factors are consistent with those applied in the derivation of AEGL-3 values for methyl isocyanate (NRC 2003). Finally, a modifying factor of 3 was applied to account for potential developmental toxicity of *n*-butyl isocyanate on the basis of data on methyl isocyanate.

Time scaling was performed using the equation $C^n \times t = k$. Default values of $n = 3$ for extrapolating to shorter durations and $n = 1$ for extrapolating to longer durations were used. Because of uncertainties associated with extrapolating a 4-h point of departure to a 10-min value, the 30-min AEGL-3 values was adopted as the 10-min value. AEGL-3 values for *n*-butyl isocyanate are presented in Table 7-20, and the calculations are presented in Appendix A.

5.6. SUMMARY OF AEGLS

5.6.1. AEGL Values and Toxicity End Points

AEGL-1 values are not recommended for *n*-butyl isocyanate or any of the other selected monoisocyanates because of insufficient data and the potential for systemic effects to occur at concentrations below those associated with irritation. AEGL-2 values for *n*-butyl isocyanate were derived by dividing the AEGL-3 values by 3, because of the lack of reliable data on AEGL-2 end points. A concentration causing no mortality in rats exposed for 4 h (Pauluhn et al. 1990) was used as the basis of AEGL-3 values for *n*-butyl isocyanate. AEGL values are summarized in Table 7-21.

TABLE 7-19 Comparison of Lethality Data on *n*-Butyl Isocyanate

Study	Sampling and Analysis Method	Follow-up (days)	No. of Animals	Highest Nonlethal Concentration (or Lowest Lethal Concentration) (ppm)	LC ₅₀ (ppm)
1 hour					
IRDC 1965	Spectrophotometry	14	6 males	1.4	3.8
Bayer AG 1978	FID	14	5 males, 5 females	39	105
Bayer AG 1978	FID	28	10 males, 10 females	None (94)	~125 ~150
4 hours					
Haskell Laboratory 1968	Impinger/GC	30	6 males	None (12.5)	15.6
Bayer AG 1978	FID	14	5 males, 5 females	None (22)	<22.5 18
Pauluhn et al. 1990	HPLC	28	20 males	14	Not applicable

TABLE 7-20 AEGL-3 Values for *n*-Butyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.31 ppm (1.3 mg/m ³)	0.31 ppm (1.3 mg/m ³)	0.25 ppm (1.0 mg/m ³)	0.16 ppm (0.65 mg/m ³)	0.078 ppm (0.32 mg/m ³)

TABLE 7-21 AEGL Values for *n*-Butyl Isocyanate^a

Classification	10 min	30 min	1 h	4 h	8 h
AEGL-1 ^b (nondisabling)	NR	NR	NR	NR	NR
AEGL-2 (disabling)	0.10 ppm (0.41 mg/m ³)	0.10 ppm (0.41 mg/m ³)	0.083 ppm (0.34 mg/m ³)	0.053 ppm (0.21 mg/m ³)	0.026 ppm (0.11 mg/m ³)
AEGL-3 (lethal)	0.31 ppm (1.3 mg/m ³)	0.31 ppm (1.3 mg/m ³)	0.25 ppm (1.0 mg/m ³)	0.16 ppm (0.65 mg/m ³)	0.078 ppm (0.32 mg/m ³)

^aWhen more than one of the monoisocyanates is detected at a scene, the lowest AEGL value should be applied to the sum total concentration of all detected monoisocyanates because of a presumed common mode of action.

^bNR, not recommended. On the basis of toxicity data on methyl isocyanate, it is plausible that exposure to *n*-butyl isocyanate may be associated with systemic toxicity at concentrations below those associated with irritation. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 value are without effect.

5.6.2. Other Exposure Criteria

Standards and guidelines for exposure to *n*-butyl isocyanate are presented in Table 7-22. Emergency response planning guidelines (ERPGs) for *n*-butyl isocyanate were derived in 1994 (AIHA 2011). The 1-h ERPG-1 value was based on an industrial hygiene survey (Haskell Laboratory 1989); this study was not used to derive AEGL values because it lacked adequate documentation. The ERPG-2 was also based on the survey study, which concluded that 0.05 ppm was not expected to impede escape. Finally, the ERPG-3 of 1 ppm is based on a calculated LC₀₁ of 6.8 ppm for rats exposed to *n*-butyl isocyanate for 4 h (Haskell Laboratory 1968). As noted earlier in this chapter, these data were not used to derive AEGL values because of the uncertainty associated with the analytic method (gas chromatograph) used to measure *n*-butyl isocyanate.

6. PHENYL ISOCYANATE

6.1. Human Toxicity Data

No information regarding lethality, nonlethal toxicity, developmental toxicity, genotoxicity, or carcinogenicity in humans after acute inhalation exposure to phenyl isocyanate was available.

TABLE 7-22 Standards and Guidelines for *n*-Butyl Isocyanate

Guideline	Exposure Duration				
	10 min	30 min	1 h	4 h	8 h
AEGL-1	NR	NR	NR	NR	NR
AEGL-2	0.10 ppm	0.10 ppm	0.083 ppm	0.053 ppm	0.026 ppm
AEGL-3	0.31 ppm	0.31 ppm	0.25 ppm	0.16 ppm	0.078 ppm
ERPG-1 (AIHA) ^a			0.01 ppm		
ERPG-2 (AIHA)			0.05 ppm		
ERPG-3 (AIHA)			1.0 ppm		

^aERPG (emergency response planning guidelines, American Industrial Hygiene Association) (AIHA 2011)

ERPG-1 is the maximum airborne concentration below which it is believed nearly all individuals could be exposed for up to 1 h without experiencing other than mild, transient adverse health effects or without perceiving a clearly defined objectionable odor.

ERPG-2 is the maximum airborne concentration below which it is believed nearly all individuals could be exposed for up to 1 h without experiencing or developing irreversible or other serious health effects or symptoms that could impair an individual's ability to take protective action.

ERPG-3 is the maximum airborne concentration below which it is believed nearly all individuals could be exposed for up to 1 h without experiencing or developing life-threatening health effects.

6.2. Animal Toxicity Data

6.2.1. Acute Lethality

Four albino rats exposed to phenyl isocyanate at a concentration of 0.33 mg/L (about 67 ppm) died after 1 h (2 rats), 2 h, and 2.5 h of exposure (SA 1954). In a second experiment, all rats survived exposure to phenyl isocyanate at 0.14 mg/L (about 29 ppm) for 4 h. Concentrations were determined by spectrophotometric analysis and comparison with a standard curve. No other information was provided in the report.

Groups of four male and four female Alderley Park rats were exposed for 1 h to phenyl isocyanate (purity not specified) in a 17-L chamber at concentrations of 0.358, 1.325, 1.45, 2.167, 4.368, 6.08, 7.942, or 9.187 ppm, and were observed for 14 days (see Table 7-23) (ICI 1977; Mobay 1978). Concentrations of phenyl isocyanate was determined by a colorimetric technique (Marcali method; phenyl isocyanate content in absorption media determined by spectrophotometric analysis and comparison with a standard curve). The 1-h LC₅₀ was estimated to be 3.9 ppm (95% CI: 2.9-5.3 ppm). Most deaths occurred 8-12 days after exposure. In a preliminary summary of this study, Mobay Corp. (1978) reported that the chamber concentrations had been analyzed by both the Marcali method and by HPLC analysis, and that the two methods gave divergent results. According to Mobay (1978), the HPLC values were closer to the calculated concentrations. The original report (ICI 1977) did not discuss analysis of the chamber concentrations by HPLC, and

Mobay (1978) did not provide individual exposure concentrations measured by HPLC. On the basis of the HPLC results, Mobay (1978) estimated a 1-h LC₅₀ of 12.6 ppm (95% CI: 8.4-19.0 ppm). Uncertainty with respect to the reliability of the Marcali method for analyzing exposure concentrations, coupled with lack of documentation on the exposure concentrations estimated by HPLC analysis, limits the use of this study for calculating AEGL values.

TABLE 7-23 Lethality in Rats Exposed to Phenyl Isocyanate for 1 Hour

Concentration ^a (ppm)	Lethality	Comments
0.358	0/8	No clinical signs; small hemorrhagic sites on lungs of one male and one female found at necropsy.
1.325	0/8	No clinical signs in females; slight body weight loss and signs of toxicity (piloerection, wheezing, hunched posture) in males; four males with evidence of lung damage at necropsy; all animals had increased lung weight.
1.45	0/8	Slight wheezing after exposure; reversible body weight loss in males; no clinical signs in females; no significant findings at necropsy.
2.167	2/4 males 2/4 females	Males: deaths on days 5 and 12; increased lung weight and focal hemorrhage. Females: deaths on days 7 and 12; increased lung weight and focal hemorrhage.
4.368	1/4 males 3/4 females	Males: death on day 8; respiratory distress; pulmonary hemorrhage; air in intestines; increased lung weight. Females: deaths on days 4, 5, 8; respiratory distress; pulmonary hemorrhage; air in intestines; increased lung weight.
6.08	2/4 males 2/4 females	Males: deaths on days 10 and 12; labored respiration; hunched posture; focal pulmonary hemorrhage; air in intestines; increased lung weight. Females: deaths on days 8 and 13; labored respiration; hunched posture; focal pulmonary hemorrhage; air in intestines; increased lung weight.
7.942	4/4 males 4/4 females	Males: deaths on days 7, 9, and 8 (two rats); signs of severe respiratory distress; all animals moribund; focal pulmonary hemorrhage; air in intestines; increased lung weight. Females: deaths on days 8 (two rats) and 12 (two rats); signs of severe respiratory distress; all animals moribund; focal pulmonary hemorrhage; air in intestines; increased lung weight.
9.187	4/4 males 3/4 females	Males: deaths on days 1, 9, 11, and 14; severe respiratory distress; moribund; necropsy findings indicative of severe pulmonary damage. Females: deaths on days 6, 9, and 14; severe respiratory distress; moribund; necropsy findings indicative of severe pulmonary damage.

^aAnalyzed by Marcali method.

Sources: Adapted from ICI 1977 and Mobay 1978.

In an experiment in which groups of five male and five female Wistar rats were exposed to a saturated atmosphere of phenyl isocyanate (about 1,600 ppm at 20°C) for 3, 10, or 30 min, all rats died (Bayer AG 1981). Time to death was inversely related to exposure duration: 8-11 days for the 3-min exposure, 3-24 h for the 10-min exposure, and 32-59 min for the 30-min exposure. The observation period was 14 days. The only gender-related differences in findings occurred in the group exposed for 10 min; male rats died as early as 3 h after exposure whereas all female rats died at 24 h. Signs of toxicity (ocular and nasal irritation and respiratory distress) appeared very quickly, and rats that survived the first week experienced body weight loss. Necropsy findings confirmed pulmonary damage.

In an acute inhalation toxicity study in rats, groups of five male and five female young adult Wistar rats were exposed to phenyl isocyanate (99.9% pure) for 4 h at measured concentrations of 0.7, 5.4, 15.2, 11.7, 27.9, 47.1, and 87.8 mg/m³ (equivalent to 0.14, 1.1, 3.1, 2.4, 5.7, 9.7, and 18 ppm) (Bayer AG 1991a). Controls were exposed to clean air only. On the basis of clinical signs and gross pathology findings, the primary target of toxicity appeared to be the respiratory tract. Most rats died within 9 days. The investigators reported a 4-h LC₅₀ of 22 mg/m³ (95% CI: 19-27 mg/m³) for males and females combined; mortality data are presented in Table 7-24. No mortality occurred at concentrations of 0.7 and 5.4 mg/m³ (0.14 and 1.1 ppm, respectively).

In summary, lethality data for phenyl isocyanate vapor are only available for rats. Lethality benchmarks for phenyl isocyanate are summarized in Table 7-25.

6.2.2. Nonlethal Toxicity

In the 4-h study of phenyl isocyanate in rats (Bayer AG 1991a) described in Section 6.2.1, no clinical signs of toxicity were observed at 0.7 mg/m³ (0.14 ppm). Exposure at 5.4 mg/m³ (1.1 ppm) resulted in slightly slowed and labored breathing in some rats. At 11 and 15.2 mg/m³ (2.4 and 3.1 ppm), these symptoms were accompanied by unkempt ruffled fur, coughing sounds, serous nasal secretions, and decreased locomotor activity, tachypnea, cyanosis, high-stepping gait, and emaciated appearance; one death occurred among the 20 rats exposed at these two concentrations. Rats in the highest exposure groups (27.9 mg/m³ [5.7 ppm] and higher), which experienced significant mortality, also exhibited rattling sounds, lethargy, and prostration. Reflex testing on the day of exposure or shortly thereafter revealed no signs of neurological effects. Marginal hypothermia was noted in rats exposed to phenyl isocyanate at 15.2 mg/m³; higher concentrations were associated with marked hypothermia as well as depressed body weight. At necropsy, inflated lungs were found in rats exposed at 15.2 mg/m³ and higher that survived the observation period. Rats that died before the observation period ended had inflated, edematous, mucous-filled lungs; hydrothorax; reddened nasal areas; bloody mucous-filled gastrointestinal tracts; reddened mucosa of the small intestines; pale liver, spleen, and kidneys; and lobular appearance of the liver.

TABLE 7-24 Lethality in Rats Exposed to Phenyl Isocyanate for 4 Hours

Exposure Concentration (ppm)	Mortality		
	Females	Males	Total
0.14	0/5	0/5	0/10
1.1	0/5	0/5	0/10
2.4	0/5	1/5	1/10
3.1	0/5	0/5	0/10
5.7	3/5	4/5	7/10
9.7	5/5	5/5	10/10
18	5/5	5/5	10/10

^aAnalyzed by high performance liquid chromatography.

Source: Bayer AG 1991a.

TABLE 7-25 Summary of Rat Lethality Benchmarks for Phenyl Isocyanate

Study (analytic method)	Lethality Benchmark	Comments
SA1954 (not specified)	1-2.5 h at 67 ppm	100% lethality
	4 h at 29 ppm	No deaths.
ICI 1977; Mobay 1978 (Marcali method and HPLC)	1-h LC ₅₀ : 12.6 ppm (by HPLC) or 3.9 ppm (by Marcali method)	Deaths at 8-12 d post-exposure
Bayer AG 1991a (HPLC)	4-h LC ₅₀ : 4.6 ppm	Most deaths at 9 d post-exposure
Bayer AG 1981 (saturated vapor; not measured)	3 min at 1,600 ppm	10/10 died at 8-11 d
	10 min at 1,600 ppm	10/10 died at 3-24 h
	30 min at 1,600 ppm	10/10 died at 32-59 min

In a pilot study by Pauluhn et al. (1995), groups of four male Wistar rats exposed (nose-only) to analytically determined phenyl isocyanate concentrations of 0, 1.9, 5.14, or 12.92 mg/m³ (0, 0.4, 1.1, and 2.7 ppm) for 45 min exhibited a concentration-related decrease in respiratory rate (approximately 20-50% decrease relative to controls). On the basis of data presented graphically, the highest exposure (12.92 mg/m³) resulted in a decrease in respiratory rate of about 50%, suggesting that the RD₅₀ for phenyl isocyanate in rats is about 13 mg/m³ (2.7 ppm). The investigators reported an estimated threshold exposure for upper respiratory tract sensory irritation of 1.1 mg/m³ (0.2 ppm). A bradypnoic response was observed, but no evidence of changes in minute volume or tidal volume were found.

6.2.3. Repeated Exposure

Groups of 10 male and 10 female young-adult Wistar rats were exposed to phenyl isocyanate at 0, 0.12, 0.57, or 3.14 mg/m³ (0, 0.03, 0.1, or 0.7 ppm) for 6

h/day for 5 days, and were observed for 3 weeks (Bayer AG 1991b). Concentrations of phenyl isocyanate were determined by HPLC analysis. No rats died at any concentration. No significant clinical signs were observed in the rats exposed at 0.03 or 0.1 ppm, and no effects on body weight or rectal temperature were found. Rats exposed at 0.7 ppm exhibited serous nasal discharge but had no cumulative effects. Lung lavage fluid and LDH analysis on days 7-8 of the experiment revealed no significant treatment-related effects in the 0.7-ppm group. Although there were no observations reported after just one exposure, results of this study indicated that multiple 6-h exposures to phenyl isocyanate at 0.1 ppm were without serious effect and multiple exposures at concentrations as high as 0.7 ppm did not result in significant toxicologic consequences.

In a study by ICI (1980), groups of eight male and eight female Alderley Park, Wistar-derived rats were exposed to phenyl isocyanate at concentrations of 0.05 ppm or 0.5 ppm for 6 h/day for 11 days. The original protocol specified a 3-week study duration, but severe respiratory distress in the rats necessitated a shorter duration. Control groups included rats exposed to clean air or petroleum ether (the diluent used with the test article). Test atmospheres were generated by heating a known amount of phenyl isocyanate and diluting the vapor with petroleum ether. Exposures were conducted in 60-L Perspex chambers that allowed for individual housing of the rats. Airflow was 15-45 L/min depending on the exposure group. Phenyl isocyanate concentrations were determined by the Marcali method, and were found to vary from the target concentrations by 25% or more. Rats in the control groups and the 0.05-ppm group exhibited no clinical signs and results of post-mortem exams were unremarkable. Two rats in the 0.5-ppm group died (on days 9 and 11), and most exhibited signs of respiratory distress and overall poor condition as early as the first exposure day. The investigators concluded that, under the conditions of this experiment, 0.05 ppm was close to a no-effect level. However, uncertainty with respect to the reliability of the Marcali analytic method limits the utility of this study for deriving AEGL values.

In a 2-week study, groups of 20 male Wistar rats were exposed (nose-only) for 6 h/day, 5 days/week to phenyl isocyanate at concentrations of 0, 1.04, 4.1, 7.18, or 10.39 mg/m³ (0, 0.2, 0.8, 1.5, or 2.1 ppm) (Pauluhn et al. 1995). With the exception of Goblet cell hyperplasia in the nasal and paranasal regions and main bronchi of rats in the 4-mg/m³ group, the incidences of histopathologic lesions in rats of the 1- or 4-mg/m³ groups was not significantly different than controls. Rats in these groups were free of clinical signs. Findings in the two highest exposure groups were indicative of significant airway injury and decrements in pulmonary function consistent with the clinical signs of respiratory-tract irritation. Most of the signs observed in the 7- and 10-mg/m³ groups regressed during the first post-exposure week, although sporadic recurrence of irregular breathing patterns and wheezing was observed. Necropsy findings in these groups included macroscopic lung lesions (hepatoid foci and red areas or complete redness of the lung surface) and pleural adhesions.

6.2.4. Developmental and Reproductive Effects

No information regarding the developmental and reproductive toxicity of phenyl isocyanate vapor in animals was available.

6.2.5. Genotoxicity

Phenyl isocyanate was not toxic in *Salmonella* at concentrations of 2,500-12,500 µg/plate. There was no significant evidence of mutagenic effects in *Salmonella*/microsome tests (Bayer AG 1980b). Results of a mouse micronucleus test revealed no evidence of a clastogenic effect from phenyl isocyanate at 30 mg/kg (Bayer AG 1990).

6.2.6. Carcinogenicity

No information regarding the carcinogenicity of phenyl isocyanate vapor in animals was available.

6.3. Data Analysis for AEGL-1

6.3.1. Human Data Relevant to AEGL-1

No data regarding AEGL-1 severity effects in humans exposed to phenyl isocyanate are available.

6.3.2. Animal Data Relevant to AEGL-1

Pauluhn et al. (1995) estimated a threshold for upper respiratory tract sensory irritation of 1.1 mg/m³ (0.2 ppm) in a study of Wistar rats exposed to phenyl isocyanate for 45 min. A bradypnoic response was observed, but no evidence of changes in minute volume or tidal volume was found. In a follow-up multiple exposure study (6 h/day, 5 days/week for 2 weeks), rats exposed to phenyl isocyanate at concentrations up to 0.2 ppm had no discernible effects (Pauluhn et al. 1995). The incidence of histopathologic lesions in the 1- or 4-mg/m³ (0.2 or 0.8 ppm) groups was not significantly different from those of controls. Rats in these exposure groups were also free of clinical signs.

6.3.3. Derivation of AEGL-1 Values

AEGL-1 values were not derived for phenyl isocyanate. The available data suggest that phenyl isocyanate and the other three selected monisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic

toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for phenyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

6.4. Data Analysis for AEGL-2

6.4.1. Human Data Relevant to AEGL-2

No information regarding AEGL-2 severity effects in humans following inhalation exposure to phenyl isocyanate was available.

6.4.2. Animal Data Relevant to AEGL-2

Studies with rats indicate that respiratory-tract irritation and subsequent tissue damage are the critical effects from exposure to phenyl isocyanate vapor. No rats died after exposure to phenyl isocyanate at 0.03, 0.1, or 0.7 ppm for 6 h/day for 5 days, and observed for 3 weeks (Bayer AG 1991b). No significant clinical signs were observed in rats exposed at 0.03 or 0.1 ppm, and no effects on body weight or rectal temperature were found. Rats exposed at 0.7 ppm exhibited serous nasal discharge but no cumulative effects. Lung lavage fluid and LDH analysis on days 7-8 revealed no significant treatment-related effects in the 0.7-ppm group. Although no observations were reported after just one exposure, results of this study indicated that multiple 6-h exposures to phenyl isocyanate at 0.1 ppm were without serious effect and multiple exposures to concentrations as high as 0.7 ppm did not result in significant toxicologic consequences. Pauluhn et al. (1995) reported that rats exposed to phenyl isocyanate up to 4 mg/m³ (0.8 ppm) for 6 h/day, 5 days/week for 2 weeks exhibited no clinical signs of toxicity, no gross lesions in the respiratory tract, no significant findings regarding BAL analysis, and no effects on organ and body weights. The only histopathologic finding was Goblet cell hyperplasia in the nasal and paranasal regions and main bronchi. In another study, hypothermia and respiratory-tract irritation were observed in rats exposed at 5 mg/m³ (1.1 ppm) for 4 h (Bayer AG 1991a).

6.4.3. Derivation of AEGL-2 Values

Animal data relevant to AEGL-2 values were available for phenyl isocyanate. However, those data would lead to 4- and 8-h AEGL-2 values that are very similar to AEGL-3 values (see below). Therefore, to provide adequate protection, AEGL-3 values were divided by 3 to derive AEGL-2 values for phenyl isocyanate. This approach is recommended by NRC (2001) for compounds with a steep concentration-response relationship. Mortality data from a study of rats exposed to phenyl isocyanate for 4 h indicates a steep relationship; no rats died at 3.1 ppm and 70% died at 5.7 ppm (Bayer AG 1991a). AEGL-2 values for

phenyl isocyanate presented in Table 7-26, and the calculations are presented in Appendix A.

If AEGL-2 values were calculated on the basis of the available animal data for phenyl isocyanate, the most relevant point of departure would be the estimated threshold for respiratory-tract injury. In the Pauluhn et al. (1995) study, 0.8 ppm would be a no-effect level for AEGL-2 severity effects. AEGL-2 values could be calculated by applying a total uncertainty factor of 30 (3 for interspecies differences and 10 for intraspecies variability), applying a modifying factor of 3 (to account for potential developmental toxicity of *n*-butyl isocyanate on the basis of data for the related compound methyl isocyanate), and performing time scaling with the equation $C^n \times t = k$ (using default values of $n = 3$ for extrapolation to shorter durations and $n = 1$ for extrapolation to longer durations). This approach would result in 4- and 8-h AEGL-2 values of 0.01 and 0.007 ppm, respectively. Because these values are very close to the 4- and 8-h AEGL-3 values of 0.018 and 0.009 ppm for this compound, this approach was not used to derive AEGL-2 values for phenyl isocyanate.

6.5. Data Analysis for AEGL-3

6.5.1. Human Data Relevant to AEGL-3

No information regarding AEGL-3 severity effects in humans following vapor exposure to phenyl isocyanate was available.

6.5.2. Animal Data Relevant to AEGL-3

Only rat lethality data are available for phenyl isocyanate. The candidate studies include a 1-h study using groups of four male and four female rats (ICI 1977; Mobay 1978) and a 4-h study using five male and five female rat (Bayer AG 1991a). ICI (1977) and Mobay (1978) reported different LC_{50} values, depending on the analytic technique used to measure phenyl isocyanate; an LC_{50} of 3.9 ppm measured by Marcali colorimetric analysis or 12.6 ppm measured by HPLC analysis. The highest nonlethal concentration was 1.45 ppm, as measured by the Marcali method. Uncertainty with respect to the reliability of the Marcali method for analyzing exposure concentrations, coupled with lack of documentation on the exposure concentrations estimated by HPLC analysis, limited the use of this study for deriving AEGL-3 values.

TABLE 7-26 AEGL-2 Values for Phenyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.012 ppm (0.058 mg/m ³)	0.012 ppm (0.058 mg/m ³)	0.0096 ppm (0.047 mg/m ³)	0.0061 ppm (0.030 mg/m ³)	0.0030 ppm (0.015 mg/m ³)

In the Bayer AG (1991a) study, groups of five male and five female young-adult Wistar rats were exposed to phenyl isocyanate for 4 h at concentrations of 0.7, 5.4, 15.2, 11.7, 27.9, 47.1, and 87.8 mg/m³ (0.14, 1.1, 3.1, 2.4, 5.7, 9.7, and 18 ppm). Concentrations were determined by HPLC analysis. The investigators reported a 4-h LC₅₀ of 22 mg/m³ (95% CI: 19-27 mg/m³); the highest nonlethal concentration was 5.4 mg/m³. Benchmark dose modeling of the data resulted in BMCL₀₅ (benchmark concentration, 95% confidence limit with a 5% response) and BMC₀₁ (benchmark concentration with 1% response) estimates of 1.64 and 1.73 ppm, respectively. This study was selected for use in deriving AEGL-3 values for phenyl isocyanate.

Monsanto (SA 1954) reported a nonlethal concentration of 29 ppm for phenyl isocyanate in a 4-h study of four rats; however, this study was not considered as a basis for deriving AEGL values because the number of animals tested was small, the sex and strain of rat were not specified, and no additional details were provided in the report. In addition, the nonlethal concentration in this study was much higher than concentrations associated with lethality (3.1 ppm and higher) in a later study with better documentation (Bayer AG 1991a).

6.5.3. Derivation of AEGL-3 Values

The 4-h BMCL₀₅ value of 1.64 ppm calculated from the rat lethality data reported by Bayer AG (1991a) was used as the basis for deriving AEGL-3 values for phenyl isocyanate. This point of departure is supported by data from a study of repeated 6-h exposures to phenyl isocyanate, in which 2.1 ppm was not lethal to 20 male rats exposed for 2 weeks (Pauluhn et al. 1995). Interspecies and intraspecies uncertainty factors of 3 and 10, respectively, were applied. An interspecies uncertainty factor of 3 was considered appropriate on the basis of mortality data on the related compound methyl isocyanate that indicated limited species differences; about a two-fold difference in 6-h LC₅₀s for rats, mice, and guinea pigs was found (see Section 2.4). A factor of 3 is also consistent with that used for deriving AEGL values for methyl isocyanate. A factor of 10 was applied to account for intraspecies variability, and was also consistent with the factor applied in the derivation of AEGL-3 values for methyl isocyanate (NRC 2003). Finally, a modifying factor of 3 was applied to account for potential developmental toxicity of phenyl isocyanate on the basis of data on methyl isocyanate.

Time scaling was performed using the equation $C^n \times t = k$, with default values of $n = 1$ for extrapolating to longer durations and $n = 3$ for extrapolating to shorter durations. Because of the uncertainties associated with extrapolating a 4-h point of departure to a 10-min value, the 30-min AEGL-3 was adopted as the 10-min value. AEGL-3 values for phenyl isocyanate are presented in Table 7-27, and the calculations are presented in Appendix A.

6.6. Summary of AEGLs

6.6.1. AEGL Values and Toxicity End Points

AEGL-1 values are not recommended for phenyl isocyanate because of insufficient data, and because of the potential for systemic effects to occur at concentrations below those associated with irritation.

Although data on AEGL-2 end points for phenyl isocyanate were available, calculations using those data would result in AEGL-2 values very close to AEGL-3 values. Therefore, AEGL-2 values were derived from the AEGL-3 values for phenyl isocyanate by dividing them by 3 to provide adequate protection. The $BMCL_{05}$ calculated using data from a 4-h lethality study (Bayer AG 1991a) was used as the point of departure for AEGL-3 values for phenyl isocyanate.

AEGL values for phenyl isocyanate are presented in Table 7-28.

6.6.2. Other Exposure Criteria

Only two exposure guidelines for phenyl isocyanate were found. The Swedish Work Environment Authority (SWEA 2005) has a level limit value (occupational limit for one working day) of 0.005 ppm and a 5-min ceiling value (occupational limit for a 5-min period) of 0.01 ppm.

TABLE 7-27 AEGL-3 Values for Phenyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.036 ppm (0.18 g)	0.036 ppm (0.18 mg/m ³)	0.029 ppm (0.14 mg/m ³)	0.018 ppm (0.088 mg/m ³)	0.0091 ppm (0.044 mg/m ³)

TABLE 7-28 AEGL Values for Phenyl Isocyanate^a

Classification	10 min	30 min	1 h	4 h	8 h
AEGL-1 ^b (nondisabling)	NR	NR	NR	NR	NR
AEGL-2 (disabling)	0.012 ppm (0.058 mg/m ³)	0.012 ppm (0.058 mg/m ³)	0.0096 ppm (0.047 mg/m ³)	0.0061 ppm (0.030 mg/m ³)	0.0030 ppm (0.015 mg/m ³)
AEGL-3 (lethal)	0.036 ppm (0.18 mg/m ³)	0.036 ppm (0.18 mg/m ³)	0.029 ppm (0.14 mg/m ³)	0.018 ppm (0.088 mg/m ³)	0.0091 ppm (0.044 mg/m ³)

^aWhen more than one of the monoisocyanates is detected at a scene, the lowest AEGL should be applied to the sum total concentration of all detected monoisocyanates because of a presumed common mode of action. Phenyl isocyanate has shown dermal sensitizing effects. Its respiratory sensitizing potential is unknown. Individuals who have a strong reaction might not be protected within the definition of effects for each level.

^bNR, not recommended. On the basis of toxicity data on methyl isocyanate, it is plausible that exposure to phenyl isocyanate may be associated with systemic toxicity at concentrations below those associated with irritation. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

7. REFERENCES

- AIHA (American Industrial Hygiene Association). 2011. Current ERPG Values. The AIHA 2011 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Handbook. American Industrial Hygiene Association, Fairfax, VA.
- Andersson, N., M.K. Muir, V. Mehra, and A.G. Salmon. 1988. Exposure and response to methyl isocyanate: Results of a community based survey in Bhopal. *Br. J. Ind. Med.* 45(7):469-475.
- ANPON (Jiangsu Anpon Electrochemical Company, Ltd). 2008. n-Butyl Isocyanate: Product Description [online]. Available: http://anpon.en.alibaba.com/product/10276009/51026270/Intermediate-ChemicalsN_Buty [accessed Jan. 25, 2008].
- Bayer AG. 1978. n-Butylisocyanat: Untersuchungen zur akuten Toxizität. Report No. 7442/3. Bayer AG Institut für Toxikologie, Wuppertal-Elberfeld, Germany. April 7, 1978. Submitted to EPA by Miles Inc., Pittsburg, PA with Cover Letter Dated 8/10/92. EPA Document No. 88-920005842. Microfiche No. OTS0543303.
- Bayer AG. 1980a. Cyclohexylisocyanat Gewerbetoxikologische Untersuchungen. Report No. 9152/5. Bayer AG Institut für Toxikologie, Wuppertal-Elberfeld, Germany. May 13, 1980. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000200. Microfiche No. OTS0528432.
- Bayer AG. 1980b. Phenylisocyanat: Salmonella/Mikrosomen-Test zur Untersuchung auf Punktmutagene Wirkung. Report No. 9170/3. Bayer AG Institut für Toxikologie, Wuppertal, Germany. May 20, 1980. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000199. Microfiche No. OTS0528431.
- Bayer AG. 1981. Phenyl Isocyanat: Untersuchungen zur Gewerbetoxikologie. Report No. 9694/5. Bayer AG Institut für Toxikologie, Wuppertal-Elberfeld, Germany. January 20, 1981. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000198. Microfiche No. OTS0528430.
- Bayer AG. 1990. Phenylisocyanate: Micronucleus Test on the Mouse. Study No. T6033839. Report No. 19566. Bayer AG. Fachbereich Toxicology, Wuppertal, Germany. September 9, 1990. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/27/90. EPA Document No. 86-10000575. Microfiche No. OTS0530311.
- Bayer AG. 1991a. Phenylisocyanat: Untersuchungen zur akuten Inhalationstoxizität an der Ratte. Study No. T7037386. Report No. 20354. Bayer AG Institut für Toxikologie, Wuppertal, Germany. June 12, 1991. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 8/16/91. EPA Document No. 88-910000236. Microfiche No. OTS0533666.
- Bayer, AG. 1991b. Phenylisocyanate: Untersuchungen zur orientierenden subakuten Inhalationstoxizität an der Ratte. Study No. T6039581. Report No. 20132. Bayer AG Institut für Toxikologie, Wuppertal, Germany. March 28, 1991. Submitted to EPA by Mobay Corporation, Pittsburgh, PA. EPA Document No. 86-910000828. Microfiche No. OTS0530419.
- Bucher, J.R., B.N. Gupta, B. Adkins, Jr., M. Thompson, C.W. Jameson, J.E. Thigpen, and B.A. Schwetz. 1987. Toxicity of inhaled methyl isocyanate in F344/N rats and B6C3F1 mice. I. Acute exposure and recovery studies. *Environ. Health Perspect.* 72:53-61.

- Crawford, C.R., and R.H. Anderson. 1974. Acute Toxicity Studies of Cyclohexyl Isocyanate. Report No. 40870. CHEMAGRO Division of Baychem Corporation, June 14, 1974. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000203. Microfiche No. OTS0528435.
- Eastman Kodak. 1964. Toxicity and Health Hazard Summary: Ethyl Isocyanate. Submitted to EPA by Eastman Kodak, Co., Rochester, NY with Cover Letter Dated 10/29/90. EPA Document No. 86-910000051. Microfiche No. OTS0528345.
- Eastman Kodak. 1990. Health and Safety Study on Cyclohexyl Isocyanate with Attachments. Submitted to EPA from Eastman Kodak Company, Rochester, NY with Cover Letter Dated 10/29/90. EPA Document No. 86-910000052. Microfiche No. OTS0528346.
- Eastman Kodak. 1992. Initial Submission: Acute Inhalation Toxicity Test with Cyclohexyl Isocyanate in Rats with Cover Letter Dated 08/10/92. Eastman Kodak Co, Rochester, NY. EPA Document No. 88-920005123. Microfiche No. OTS0544097.
- Ferguson, J.S., M. Schaper, M.F. Stock, D.A. Weyel, and Y. Alarie. 1986. Sensory and pulmonary irritation with exposure to methyl isocyanate. *Toxicol. Appl. Pharmacol.* 82(2):329-335.
- Fowler, E.H., and D.E. Dodd. 1986. Acute inhalation studies with methyl isocyanate vapor. II. Respiratory tract changes in guinea pigs, rats, and mice. *Fundam. Appl. Toxicol.* 6(4):756-771.
- Haskell Laboratory. 1968. Acute Inhalation Toxicity of Isocyanic Acid Butyl Ester in Rats. Haskell Laboratory for Toxicology and Industrial Medicine Report No. 289-68. MR No. 581-243. December 19, 1968. Submitted to EPA by DuPont, Wilmington, DE with Cover Letter Dated 10/15/92. EPA Document No. 88-9200010305. Microfiche No. OTS 0571701.
- Haskell Laboratory. 1982. Guinea Pig Respiratory Response to Isocyanates. Report No. 681-81. Du Pont de Nemours and Co., Haskell Laboratory for Toxicology and Industrial Medicine, Newark, DE. January 5, 1982. Submitted to EPA by DuPont, Wilmington, DE, with Cover Letter Dated 12/26/90. EPA Document No. 86-910000448. Microfiche No. OTS 0530206.
- Haskell Laboratory. 1989. Butyl Isocyanate Industrial Hygiene Survey. Letter to G.L. Kennedy, from D.P. Kelly, Central Research and Development Department, Haskell Laboratory for Toxicology and Industrial Medicine. January 4, 1989.
- Horspool, G.M., and J.E. Doe. 1977. Toluene Di-isocyanate: Acute Inhalation Toxicity in the Rat. Study No. HR0082. Report No. CTL/T/1097. Imperial Chemicals Industries Limited, Central Toxicology Laboratory, Macclesfield, Cheshire, UK.
- HSDB (Hazardous Substances Data Bank). 2007a. Ethyl Isocyanate. CAS No. 109-90-0. TOXNET, Specialized Information Services, U.S. Library of Medicine, Bethesda, MD [online]. Available: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB> [accessed May 6, 2013].
- HSDB (Hazardous Substances Data Bank). 2007b. n-Butyl Isocyanate. CAS No. 111-36-4. TOXNET, Specialized Information Services, U.S. Library of Medicine, Bethesda, MD [online]. Available: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB> [accessed May 6, 2013].
- HSDB (Hazardous Substances Data Bank). 2012. Phenyl Isocyanate. CAS No. 103-71-9. TOXNET, Specialized Information Services, U.S. Library of Medicine, Bethesda, MD [online]. Available: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB> [accessed May 6, 2013].

- HSDB (Hazardous Substances Data Bank). 2013. Cyclohexylisocyanate. CAS No. 3173-53-3. TOXNET, Specialized Information Services, U.S. Library of Medicine, Bethesda, MD [online]. Available: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB> [accessed May 6, 2013].
- ICI (Imperial Chemical Industries, Ltd). 1977. Phenyl Isocyanate: Acute Inhalation Toxicity. Study No. HR0081. Report No. CTL/T/1098. Imperial Chemical Industries, Ltd., Central Toxicology Laboratory, Macclesfield, Cheshire, UK. October 1977. Submitted to EPA by Mobay Corporation, Pittsburgh, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000202. Microfiche No. OTS 0528434.
- ICI (Imperial Chemical Industries, Ltd). 1980. Phenyl Isocyanate: Subacute Inhalation Toxicity Study in Rats. Study No. MR0004. Report. No. CTL/T/1349. Imperial Chemical Industries, Ltd., Central Toxicology Laboratory, Macclesfield, Cheshire, UK. Submitted to EPA by Dow Chemical Company with Cover Letter Dated 06/04/92. EPA Document No. 88-920003412. Microfiche No. OTS0540063.
- IPCS (International Programme on Chemical Safety). 1997. Cyclohexyl isocyanate. International Chemical Safety Card ICSC: 0856 [online]. Available: <http://www.inchem.org/documents/icsc/icsc/eics0856.htm> [accessed May 6, 2013].
- IPCS (International Programme on Chemical Safety). 2002. Phenyl Isocyanate. International Chemical Safety Card ICSC: 1131 [online]. Available: <http://www.inchem.org/documents/icsc/icsc/eics1131.htm> [accessed May 6, 2013].
- IRDC (International Research and Development Corporation). 1965. Acute Inhalation Toxicity (LC₅₀) in the Male Albino Rat: PAPI, MDI (Pure, Distilled), MDI (Precut, 3% total) and BUNCO (n-Butyl isocyanate). Report No. 203-004. January 29, 1965. Submitted to EPA by Dow Chemical Company, Midland, MI with Cover Letter Dated 8/17/92. EPA Document No. 88-920005285. Microfiche No. OTS 0544179.
- Kamat, S.R., A.A. Mahashur, A.K. Tiwaris, P.V. Potdar, M. Gaur, V.P. Kolhatkar, P. Vaidya, D. Parmar, R. Rupwate, T.S. Chatterjee, K. Jain, M.D. Kelkar, and S.G. Kinare. 1985. Early observations on pulmonary changes and clinical morbidity due to the isocyanate gas leak at Bhopal. *J. Postgrad. Med.* 31(2):63-72.
- Kamat, S.R., M.H. Patel, P.V. Pradhan, S.P. Taskar, P.R. Vaidya, V.P. Kolhatkar, J.P. Gopalani, J.P. Chandarana, N. Dalal, and M. Naik. 1992. Sequential respiratory, psychologic, and immunologic studies in relation to methyl isocyanate exposure over two years with model development. *Environ. Health Perspect.* 97:241-253.
- Karol, M.H., and J.A. Kramarik. 1996. Phenyl isocyanate is a potent chemical sensitizer. *Toxicol. Lett.* 89(2):139-146.
- Kennedy, A.L., G. Singh, Y. Alarie, and W.E. Brown. 1993. Autoradiographic analyses of guinea pig airway tissues following inhalation exposure to ¹⁴C-labeled methyl isocyanate. *Fundam. Appl. Toxicol.* 20(1):57-67.
- Kimmerle, G., and A. Eben. 1964. On the toxicity of methyl isocyanate and its quantitative determination in air [in German]. *Arch. Toxikol.* 20:235-241.
- Litchfield, J.T., and F. Wilcoxon. 1949. Simplified method of evaluating dose-effect experiments. *J. Pharmacol. Exp. Ther.* 96(2): 99-113.
- Lorin, H.G., and P.E. Kulling. 1986. The Bhopal tragedy – what has Swedish disaster medicine planning learned from it? *J. Emerg. Med.* 4(4):311-316.
- Mellon Institute. 1963. The Feasibility of Using Methyl Isocyanate as a Warning Agent in Liquid Carbon Monoxide. Special Report 26-23. March 15, 1963. Submitted to EPA by Rhone-Poulenc, Inc., Princeton, NJ with Cover Letter Dated 12/7/90. EPA Document No. 86-910000271. Microfiche No. OTS0528503.

- Mellon Institute. 1970. Acute Inhalation Toxicity, Human Response to Low Concentrations, Guinea Pig Sensitization, and Cross Sensitization to Other Isocyanates. Special Report 33-19. March 6, 1970. Submitted to EPA by Rhone-Poulenc, Inc., Princeton, NJ with Cover Letter Dated 12/7/90. EPA Document No. 86-910000268. Microfiche No. OTS0528500.
- Misra, N.P., R. Pathak, K.J. Gaur, S.C. Jain, S.S. Yesikar, P.C. Manoria, K.N. Sharma, B.M. Tripathi, B.S. Asthana, H.H. Trivedi, V.K. Sharma, Y. Malhotra, A. Verma, D.K. Bhargava, and G. Batni. 1987. Clinical profile of gas leak victims in acute phase after Bhopal episode. *Indian J. Med. Res.* 86(suppl.):11-19.
- Mobay. 1961. Toxicity and Safe Handling of Isocyanates. Mobay Chemical Company, Pittsburgh, PA. EPA Document No. FYI-0794-1022. Microfiche No. OTS0001022.
- Mobay, 1978. Letter to EPA from Mobay Chemical Corporation Submitting Information on Phenyl Isocyanate with Attachments. June 8, 1978. EPA Document No. 88-7800178. Microfiche No. 0200682.
- Nehez, M., G.W. Fischer, I. Nehez, H. Scheufler, and I. Desi. 1989. Investigations on the acute toxic, cytogenetic, and embryotoxic activity of phenyl isocyanate and diethoxyphosphoryl isocyanate. *Ecotoxicol. Environ. Saf.* 17(2):258-263.
- Nemery, B., S. Sparrow, and D. Dinsdale. 1985. Methyl isocyanate: Thiosulphate does not protect. *Lancet* 326(8466):1245-1246.
- NRC (National Research Council). 1993. Guidelines for Developing Community Emergency Exposure Levels for Hazardous Substances. Washington, DC: National Academy Press.
- NRC (National Research Council). 2001. Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals. Washington, DC: National Academy Press.
- NRC (National Research Council). 2003. Methyl isocyanate. Pp. 384-443 in *Acute Exposure Guideline Levels Selected Airborne Chemicals, Vol. 3*. Washington, DC: National Academies Press.
- NRC (National Research Council). 2004. Toluene 2,4- and 2,6-diisocyanate. Pp. 198-249 in *Acute Exposure Guideline Levels Selected Airborne Chemicals, Vol. 4*. Washington, DC: National Academies Press.
- OECD (Organization for Economic Co-Operation and Development). 2005. Investigation of High Production Volume Chemicals. SIDS Initial Assessment Profile: *n*-Butyl isocyanate, CAS Reg. No. 111-36-4. Organization for Economic Co-Operation and Development, Paris, France.
- Pauluhn, J., and A. Eben. 1991. Altered Lung Function in Rats after Subacute Exposure to *n*-Butyl Isocyanate. Bayer AG, Wuppertal, Germany. Submitted to EPA by Mobay Corporation, Pittsburgh, PA, with Cover Letter Dated 06/06/91. EPA Document No. 86-910000864. Microfiche No. OTS0530451.
- Pauluhn, J., A. Eben, and G. Kimmerle. 1990. Functional, biochemical, and histological evidence of airway obstruction in rats following a four-hour acute inhalation exposure to *n*-butyl isocyanate. *Exp. Pathol.* 40(4):197-203.
- Pauluhn, J., W. Rüngeler, and U. Mohr. 1995. Phenyl isocyanate-induced asthma in rats following a 2-week exposure period. *Fundam. Appl. Toxicol.* 24(2):217-228.
- Richter, R.H. 1986. Isocyanates. *Kirk-Othmer Encyclopedia of Chemical Technology*. New York: John Wiley & Sons, Inc.
- SA (Scientific Associates). 1954. Toxicological Investigations of Octadecyl Isocyanate and Phenyl Isocyanate. Monsanto Project No. SA-39. Scientific Associates, St. Louis, MO. June 17, 1954. Submitted to EPA by Monsanto Company, St. Louis,

- MO with Cover Letter Dated 08/11/92. EPA Document No. 88-920007667. Microfiche No. OTS0545863.
- Sigma Aldrich. 2012. Material Safety Data Sheet for Cyclohexyl Isocyanate. Sigma Aldrich [online]. Available: http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=C105198%7CALDRICH&N25=0&QS=ON&F=SPEC [accessed May 6, 2013].
- SWEA (Swedish Work Environment Authority). 2005. P. 46 in Occupational Exposure Limit Value and Measures against Air Contaminants. AFS 2005:17 [online]. Available: <http://www.av.se/dokument/inenglish/legislations/eng0517.pdf> [accessed May 7, 2013].
- ten Berge, W.F., A. Zwart, and L.M. Appelman. 1986. Concentration-time mortality response relationship of irritant and systemically acting vapours and gases. *J. Hazard. Mater.* 13(3):301-309.
- Varma, D.R. 1989. Hydrogen cyanide and Bhopal. *Lancet* 2(8662):567-568.
- Varma, D.R., and I. Guest. 1993. The Bhopal accident and methyl isocyanate toxicity. *J. Toxicol. Environ. Health* 40(4):513-529.
- Varma, D.R., J.S. Ferguson, and Y. Alarie. 1988. Inhibition of methyl isocyanate toxicity in mice by starvation and dexamethasone but not by sodium thiosulfate, atropine, and ethanol. *J. Toxicol. Environ. Health* 24(1):93-101.
- Weill, H. 1987. Disaster at Bhopal: The accident, early findings and respiratory health outlook in those injured. *Bull. Eur. Physiopathol. Respir.* 23(6):587-590.
- Younger Laboratories. 1956. Toxicological Investigation of n-Butyl Isocyanate. Younger Laboratories, Saint Louis, MO. September 10, 1956. Monsanto Project No. Y-56-55. Submitted to EPA by Monsanto Chemical Company, Pittsburg, PA, with Cover Letter Dated 12/10/90. EPA Document No. 86-910000209. Microfiche No. OTS0528441.
- Younger Laboratories, 1974. Toxicological Investigation of Cyclohexyl Isocyanate. Younger Laboratories, Saint Louis, MO, October 31, 1974. Submitted to EPA by Mobay Corporation, Pittsburg, PA with Cover Letter Dated 12/10/90. EPA Document No. 86-910000204. Microfiche No. OTS0528436.
- Zoltán, G., and C.D. Klaassen. 2001. Mechanisms of toxicity. P. 35-82 in Casarett and Doull's *Toxicology: The Basic Science of Poisons*, 6th Ed., C.D. Klaassen, ed. New York: McGraw-Hill.

APPENDIX A**DERIVATION OF AEGL VALUES FOR
SELECTED MONOISOCYANATES****Ethyl Isocyanate****Derivation of AEGL-1 Values**

AEGL-1 values were not derived for ethyl isocyanate because of insufficient data. The available data suggest that ethyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for ethyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

Derivation of AEGL-2 Values

The toxicologic database on ethyl isocyanate was inadequate to derive AEGL-2 values. AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate.

Calculations:

10-min AEGL-2:	$0.40 \text{ ppm} \div 2 = 0.20 \text{ ppm}$
30-min AEGL-2:	$0.13 \text{ ppm} \div 2 = 0.065 \text{ ppm}$
1-h AEGL-2:	$0.067 \text{ ppm} \div 2 = 0.034 \text{ ppm}$
4-h AEGL-2:	$0.017 \text{ ppm} \div 2 = 0.0085 \text{ ppm}$
8-h AEGL-2:	$0.008 \text{ ppm} \div 2 = 0.0040 \text{ ppm}$

Derivation of AEGL-3 Values

The toxicologic database on ethyl isocyanate was inadequate to derive AEGL-3 values. As discussed in Section 2.3 (Structure-Activity Relationships), ethyl isocyanate and the three other monoisocyanates considered in this chapter

are structurally similar to and exert toxic effects comparable to methyl isocyanate. AEGL-3 values were determined by using the AEGL-3 values established for methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate. A comparison of the available lethality data on the two chemicals suggests that this approach results in sufficiently protective AEGL values. When groups of three rats were exposed to ethyl isocyanate for 6 h, all rats survived at 27 ppm and no rats survived at 82 ppm. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats (6/sex) was 6.1 ppm (NRC 2003).

Calculations:

10-min AEGL-3:	$1.2 \text{ ppm} \div 2 = 0.60 \text{ ppm}$
30-min AEGL-3:	$0.40 \text{ ppm} \div 2 = 0.20 \text{ ppm}$
1-h AEGL-3:	$0.20 \text{ ppm} \div 2 = 0.10 \text{ ppm}$
4-h AEGL-3:	$0.050 \text{ ppm} \div 2 = 0.025 \text{ ppm}$
8-h AEGL-3:	$0.025 \text{ ppm} \div 2 = 0.013 \text{ ppm}$

Cyclohexyl Isocyanate

Derivation of AEGL-1 Values

AEGL-1 values were not derived for cyclohexyl isocyanate because of insufficient data. The available data suggest that cyclohexyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for cyclohexyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

Derivation of AEGL-2 Values

The toxicologic database on cyclohexyl isocyanate was inadequate to derive AEGL-2 values. AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate.

Calculations:

10-min AEGL-2:	$0.40 \text{ ppm} \div 2 = 0.20 \text{ ppm}$
30-min AEGL-2:	$0.13 \text{ ppm} \div 2 = 0.065 \text{ ppm}$
1-h AEGL-2:	$0.067 \text{ ppm} \div 2 = 0.034 \text{ ppm}$
4-h AEGL-2:	$0.017 \text{ ppm} \div 2 = 0.0085 \text{ ppm}$
8-h AEGL-2:	$0.008 \text{ ppm} \div 2 = 0.0040 \text{ ppm}$

Derivation of AEGL-3 Values

The toxicologic database on cyclohexyl isocyanate was inadequate to derive AEGL-3 values. AEGL-3 values were determined by using the AEGL-3 values established for methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2 to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate. A comparison of the available lethality data on the two chemicals suggests that this approach results in sufficiently protective AEGL values. When three rats were exposed to cyclohexyl isocyanate at 18 ppm for 6 h, one died on day 7 post-exposure and the other two were killed on day 8, presumably because of moribund condition. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats is 6.1 ppm (NRC 2003).

Calculations:

10-min AEGL-3:	$1.2 \text{ ppm} \div 2 = 0.60 \text{ ppm}$
30-min AEGL-3:	$0.40 \text{ ppm} \div 2 = 0.20 \text{ ppm}$
1-h AEGL-3:	$0.20 \text{ ppm} \div 2 = 0.10 \text{ ppm}$
4-h AEGL-3:	$0.050 \text{ ppm} \div 2 = 0.025 \text{ ppm}$
8-h AEGL-3:	$0.025 \text{ ppm} \div 2 = 0.013 \text{ ppm}$

n*-Butyl Isocyanate*Derivation of AEGL-1 Values**

AEGL-1 values were not derived for *n*-butyl isocyanate because of insufficient data. The available data suggest that *n*-butyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1

values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for *n*-butyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

Derivation of AEGL-2 Values

The toxicologic database on *n*-butyl isocyanate was inadequate to derive AEGL-2 values. In particular, the 4-h study by Pauluhn et al. (1990) lacked data on the incidence and severity of histopathologic findings. AEGL-2 values were determined by dividing the AEGL-3 values for *n*-butyl isocyanate by 3 (NRC 2001). This approach is justified by the steep concentration-response curve observed in mortality studies; no rats died after a 1-h exposure at 39 ppm, and 70% (7/10) died at 130 ppm (Bayer AG 1978).

Calculations:

10-min AEGL-2:	$0.31 \text{ ppm} \div 3 = 0.10 \text{ ppm}$
30-min AEGL-2:	$0.31 \text{ ppm} \div 3 = 0.10 \text{ ppm}$
1-h AEGL-2:	$0.25 \text{ ppm} \div 3 = 0.083 \text{ ppm}$
4-h AEGL-2:	$0.16 \text{ ppm} \div 3 = 0.053 \text{ ppm}$
8-h AEGL-2:	$0.078 \text{ ppm} \div 3 = 0.026 \text{ ppm}$

Derivation of AEGL-3 Values

Key study:	Pauluhn, J., A. Eben, and G. Kimmerle. 1990. Functional, biochemical, and histological evidence of airway obstruction in rats following a four-hour acute inhalation exposure to <i>n</i> -butyl isocyanate. <i>Exp. Pathol.</i> 40:197-203.
Critical effect:	Highest nonlethal concentration (14 ppm) in a 4-h rat study. Study tested more animals and used a more reliable analytic method (HPLC analysis) to measure concentrations of <i>n</i> -butyl isocyanate than other studies.

Time scaling:	<p>The exposure concentration-exposure duration relationship for many irritant and systemically acting vapors and gases may be described by the equation $C^n \times t = k$, where the exponent n ranges from 0.8 to 3.5 (ten Berge et al. 1986). In the absence data to determine an empirical value of n, default values of $n = 1$ for extrapolating to longer durations and $n = 3$ for extrapolating to shorter durations were used. The 10-min AEGL-3 value was set equal to the 30-min value because of the uncertainties associated with extrapolating a 4-h point of departure to a 10-min value (NRC 2001).</p> <p>$(14 \text{ ppm})^1 \times 4 \text{ h} = 56 \text{ ppm-h}$ $(14 \text{ ppm})^3 \times 4 \text{ h} = 10,976 \text{ ppm-h}$</p>
Uncertainty factors:	<p>3 for interspecies differences; 6-h LC_{50}s for the related compound methyl isocyanate differed about two-fold between rats, mice, and guinea pigs (see Section 2.4). A factor of 3 is also consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).</p> <p>10 for intraspecies variability; this factor is consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).</p>
Modifying factor:	3 to account for potential developmental toxicity of <i>n</i> -butyl isocyanate, on the basis of data on methyl isocyanate.
Calculations:	
10-min AEGL-3:	0.31 ppm (set equal to the 30-min AEGL-3)
30-min AEGL-3:	$C^3 \times 0.5 \text{ h} = 10,976 \text{ ppm-h}$ $C = 28 \text{ ppm}$ $28 \text{ ppm} \div 90 = 0.31 \text{ ppm}$
1-h AEGL-3:	$C^3 \times 1 \text{ h} = 10,976 \text{ ppm-h}$ $C = 22 \text{ ppm}$ $22 \text{ ppm} \div 90 = 0.25 \text{ ppm}$

Selected Monoisocyanates

253

$$4\text{-h AEGL-3: } 14 \text{ ppm} \div 90 = 0.16 \text{ ppm}$$

$$8\text{-h AEGL-3: } C^1 \times 8 \text{ h} = 56 \text{ ppm-h}$$

$$C = 7 \text{ ppm}$$

$$7 \text{ ppm} \div 90 = 0.078 \text{ ppm}$$

Phenyl Isocyanate**Derivation of AEGL-1 Values**

AEGL-1 values were not derived for phenyl isocyanate because of insufficient data. The available data suggest that phenyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for phenyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

Derivation of AEGL-2 Values

Data on phenyl isocyanate were not used to derive AEGL-2 value because they would lead to 4- and 8-h AEGL-2 values that are very similar to AEGL-3 values (see below). Therefore, AEGL-3 values for phenyl isocyanate were divided by 3 to derive AEGL-2 values. This approach is justified by the steep concentration-response curve observed in mortality studies; in a 4-h study, no rats (0/10) died after exposure at 3.1 ppm and 70% (7/10) died after exposure at 5.7 ppm (Bayer AG 1991a).

If AEGL-2 values were to be calculated from animal data for phenyl isocyanate, the point of departure would be a no-effect level of 0.8 ppm identified in a repeated exposure study (Pauluhn et al. 1995). An uncertainty factor of 3 for interspecies differences and a factor of 10 intraspecies variability would be applied. Time scaling would be performed using the equation $C^n \times t = k$, with default values of $n = 3$ for extrapolating to shorter durations and $n = 1$ for extrapolating to longer durations. This approach would lead to 4- and 8-h AEGL-2 values of 0.01 and 0.007 ppm, respectively. These values are very close to the AEGL-3 values of 0.018 and 0.009 ppm for this compound, so this approach was not used to derive AEGL values.

Calculations:

$$10\text{-min AEGL-2: } 0.036 \text{ ppm} \div 3 = 0.012 \text{ ppm}$$

254

Acute Exposure Guideline Levels

30-min AEGL-2:	$0.036 \text{ ppm} \div 3 = 0.012 \text{ ppm}$
1-h AEGL-2:	$0.029 \text{ ppm} \div 3 = 0.0096 \text{ ppm}$
4-h AEGL-2:	$0.018 \text{ ppm} \div 3 = 0.0061 \text{ ppm}$
8-h AEGL-2:	$0.0091 \text{ ppm} \div 3 = 0.0030 \text{ ppm}$

Derivation of AEGL-3 Values

Key study:	Bayer, AG. 1991a. Phenyl isocyanate; Untersuchungen zur akuten inhalationstoxizität an der Ratte. Report No.. 20354. Study No. T7037386, Bayer AG Institut für Toxikologie, Wuppertal-Elberfeld, Germany.
Critical effect:	Estimated lethality threshold in rats (4-h BMCL ₀₅ of 1.64 ppm)
Time scaling:	The exposure concentration-exposure duration relationship for many irritant and systemically acting vapors and gases may be described by the equation $C^n \times t = k$, where the exponent n ranges from 0.8 to 3.5 (ten Berge et al. 1986). In the absence data to determine an empirical value of n, default values of n = 1 for extrapolating to longer durations and n = 3 for extrapolating to shorter durations were used. The 10-min AEGL-3 value was set equal to the 30-min value because of the uncertainties associated with extrapolating a 4-h point of departure to a 10-min value (NRC 2001). $(1.64 \text{ ppm})^1 \times 4 \text{ h} = 6.56 \text{ ppm-h}$ $(1.64 \text{ ppm})^3 \times 4 \text{ h} = 17.644 \text{ ppm-h}$
Uncertainty factors:	3 for interspecies differences; 6-h LC _{50S} for the related compound methyl isocyanate differed about two-fold between rats, mice, and guinea pigs; see Section 2.4). A factor of 3 is also consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Selected Monoisocyanates

255

10 for intraspecies variability; this factor is consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Modifying factor: 3 to account for potential developmental toxicity of phenyl isocyanate, on the basis of data on methyl isocyanate.

Calculations:

10-min AEGL-3: Set equal to the 30-min AEGL-3 of 0.036 ppm

30-min AEGL-3: $C^3 \times 0.5 \text{ h} = 17.644 \text{ ppm-h}$
 $C = 3.2 \text{ ppm}$
 $3.2 \text{ ppm} \div 90 = 0.036 \text{ ppm}$

1-h AEGL-3: $C^3 \times 1 \text{ h} = 17.644 \text{ ppm-h}$
 $C = 2.6 \text{ ppm}$
 $2.6 \text{ ppm} \div 90 = 0.029 \text{ ppm}$

4-h AEGL-3: $C \times 4 \text{ h} = 6.56 \text{ ppm-h}$
 $C = 1.64 \text{ ppm}$
 $1.64 \text{ ppm} \div 90 = 0.018 \text{ ppm}$

8-h AEGL-3: $C \times 8 \text{ h} = 6.56 \text{ ppm-h}$
 $C = 0.82 \text{ ppm}$
 $0.82 \text{ ppm} \div 90 = 0.0091 \text{ ppm}$

APPENDIX B

ACUTE EXPOSURE GUIDELINE LEVELS FOR
SELECTED MONOISOCYANATES

Derivation Summary for Ethyl Isocyanate

AEGL-1 Values for Ethyl Isocyanate

10 min	30 min	1 h	4 h	8 h
NR	NR	NR	NR	NR

Data adequacy: AEGL-1 values were not derived for ethyl isocyanate because of inadequate data. The available data suggest that ethyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for ethyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

AEGL-2 Values for Ethyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.20 ppm (0.58 mg/m ³)	0.065 ppm (0.19 mg/m ³)	0.034 ppm (0.099 mg/m ³)	0.0085 ppm (0.025 mg/m ³)	0.0040 ppm (0.012 mg/m ³)

Modifying factor: 2, to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate.

Data adequacy: The toxicologic database on ethyl isocyanate was inadequate to derive AEGL-2 values. AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2.

AEGL-3 Values for Ethyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.60 ppm (1.7 mg/m ³)	0.20 ppm (0.58 mg/m ³)	0.10 ppm (0.29 mg/m ³)	0.025 ppm (0.073 mg/m ³)	0.013 ppm (0.038 mg/m ³)

Modifying factor: 2, to account for the possibility that ethyl isocyanate might be more toxic than methyl isocyanate.

Data adequacy: The toxicologic database for ethyl isocyanate was inadequate to derive AEGL-3 values. As discussed in Section 2.3 (Structure-Activity Relationships), ethyl isocyanate and the other three monoisocyanates considered in this chapter are structurally similar to and exert toxic effects comparable to methyl isocyanate.

A comparison of the available lethality data on the chemicals suggests that use of methyl isocyanate as a surrogate for ethyl isocyanate and applying a modifying factor of 2 to account for potentially higher toxicity results in sufficiently protective AEGL values. When groups of three rats were exposed to ethyl isocyanate for 6 h, all rats survived at 27 ppm and no rats survived at 82 ppm. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats (6/sex) was 6.1 ppm (NRC 2003).

Derivation Summary for Cyclohexyl Isocyanate

AEGL-1 Values for Cyclohexyl Isocyanate

10 min	30 min	1 h	4 h	8 h
NR	NR	NR	NR	NR

Data adequacy: AEGL-1 values were not derived for cyclohexyl isocyanate because of inadequate data. The available data suggest that cyclohexyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for cyclohexyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

AEGL-2 Values for Cyclohexyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.20 ppm (1.0 mg/m ³)	0.065 ppm (0.33 mg/m ³)	0.034 ppm (0.17 mg/m ³)	0.0085 ppm (0.043 mg/m ³)	0.0040 ppm (0.020 mg/m ³)

Modifying factor: 2, to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate.

Data adequacy: The toxicologic database for cyclohexyl isocyanate was inadequate to derive AEGL-2 values. AEGL-2 values were determined by using the AEGL-2 values established for the related compound methyl isocyanate (NRC 2003) and dividing them by a modifying factor of 2.

AEGL-3 Values for Cyclohexyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.60 ppm (3.1 mg/m ³)	0.20 ppm (1.0 mg/m ³)	0.10 ppm (0.51 mg/m ³)	0.025 ppm (0.13 mg/m ³)	0.013 ppm (0.066 mg/m ³)

Modifying factor: 2, to account for the possibility that cyclohexyl isocyanate might be more toxic than methyl isocyanate.

(Continued)

AEGL-3 Values for Cyclohexyl Isocyanate Continued

Data adequacy: The toxicologic database for cyclohexyl isocyanate was inadequate to derive AEGL-3 values. AEGL-3 values were determined by using the AEGL-3 values established for the related compound methyl isocyanate and dividing them by a modifying factor of 2. A comparison of the available lethality data on the two chemicals suggests that this approach results in sufficiently protective AEGL values. When three rats were exposed to cyclohexyl isocyanate at 18 ppm for 6 h, one died on day 7 post-exposure and the other two were killed on day 8, presumably because of moribund condition. For comparison, the 6-h LC₅₀ for methyl isocyanate in rats is 6.1 ppm (NRC 2003).

Derivation Summary for *n*-Butyl Isocyanate

AEGL-1 Values for *n*-Butyl Isocyanate

10 min	30 min	1 h	4 h	8 h
NR	NR	NR	NR	NR

Data adequacy: AEGL-1 values were not derived for *n*-butyl isocyanate because of inadequate data. The available data suggest that *n*-butyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for *n*-butyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

AEGL-2 Values for *n*-Butyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.10 ppm (0.41 mg/m ³)	0.10 ppm (0.41 mg/m ³)	0.083 ppm (0.34 mg/m ³)	0.053 ppm (0.21 mg/m ³)	0.026 ppm (0.11 mg/m ³)

Data adequacy: The toxicologic database on *n*-butyl isocyanate was inadequate to derive AEGL-2 values. In particular, the 4-h study by Pauluhn et al. (1990) lacked data on the incidence and severity of histopathologic findings. In the absence of adequate data, the AEGL-3 values for *n*-butyl isocyanate were divided by 3 to derive AEGL-2 values (NRC 2001). This approach is justified by the steep concentration-response curve observed in mortality studies; no rats died after a 1-h exposure at 39 ppm, and 70% (7/10) died at 130 ppm (Bayer AG 1978).

AEGL-3 Values for *n*-Butyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.31 ppm (1.3 mg/m ³)	0.31 ppm (1.3 mg/m ³)	0.25 ppm (1.0 mg/m ³)	0.16 ppm (0.6 mg/m ³)	0.078 ppm (0.32 mg/m ³)

Reference: Pauluhn, J., A. Eben, and G. Kimmerle. 1990. Functional, biochemical, and histological evidence of airway obstruction in rats following a four-hour acute inhalation exposure to *n*-butyl isocyanate. *Exp. Pathol.* 40:197-203.

Test species/Strain/Sex/Number: Rat, Wistar, males, 20/group

Exposure route/Concentrations/Durations: Inhalation; 0, 8, 25, 50 mg/m³ (0, 1.9, 5.9, 14 ppm) for 4 h

Effects: No deaths (assessed up to 28 days post-exposure)

End point/Concentration/Rationale: Estimated lethality threshold of 14 ppm (4-h nonlethal concentration). Study tested more animals, had a 28-day follow-up period, and used a more reliable analytic method (HPLC analysis) to measure concentrations of *n*-butyl isocyanate than other studies.

Uncertainty factors/Rationale:

Total uncertainty factor: 30

Interspecies: 3, because 6-h LC₅₀s for the related compound methyl isocyanate differed about two-fold between rats, mice, and guinea pigs (see Section 2.4). A factor of 3 is also consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Intraspecies: 10, is consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Modifying factor: 3, to account for potential developmental toxicity of *n*-butyl isocyanate on the basis of data on methyl isocyanate.

Animal-to-human dosimetric adjustment: Not applicable

Time scaling: $C^n \times t = k$; default values of $n = 1$ for extrapolating to longer durations and $n = 3$ for extrapolating to shorter durations. The 10-min AEGL-3 value was set equivalent to the 30-min value because of uncertainties associated with extrapolating a 4-h point of departure to a 10-min value (NRC 2001).

Data adequacy: Although lethal and nonlethal toxicity data are available for only one species, data on the related compound methyl isocyanate provide support for the AEGL derivations.

Derivation Summary for Phenyl Isocyanate**AEGL-1 Values for Phenyl Isocyanate**

10 min	30 min	1 h	4 h	8 hr
NR	NR	NR	NR	NR

Data adequacy: AEGL-1 values were not derived for phenyl isocyanate because of inadequate data. The available data suggest that phenyl isocyanate and the three other selected monoisocyanates exert toxic effects, including delayed lethality, that are similar to those induced by methyl isocyanate (see Section 2.3). AEGL-1 values were

(Continued)

AEGL-1 Values for Phenyl Isocyanate Continued

not derived for methyl isocyanate because it has poor warning properties, and because systemic toxicity is possible at concentrations lower than those associated with AEGL-1 effects (NRC 2003). On the basis of similarities between the selected monoisocyanates and methyl isocyanate, AEGL-1 values were not derived for phenyl isocyanate. Absence of AEGL-1 values does not imply that concentrations below the AEGL-2 values are without effect.

AEGL-2 Values for Phenyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.012 ppm (0.058 mg/m ³)	0.012 ppm (0.058 mg/m ³)	0.0096 ppm (0.047 mg/m ³)	0.0061 ppm (0.030 mg/m ³)	0.0030 ppm (0.015 mg/m ³)

Data adequacy: AEGL-3 values for phenyl isocyanate were divided by 3 to derive AEGL-2 values (NRC 2001). This approach is justified by the steep concentration-response relationship; in a 4-h lethality study in rats, there was no mortality (0/10) at 3.1 ppm and 70% (7/10) mortality at 5.7 ppm (Bayer AG 1991a). If AEGL-2 values were to be calculated from animal data on phenyl isocyanate, the point of departure would be a no-effect level of 0.8 ppm identified in a repeated exposure study (Pauluhn et al. 1995). An uncertainty factor of 3 for interspecies differences and a factor of 10 intraspecies variability would be applied. Time scaling would be performed using the equation $C^n \times t = k$, with default values of $n = 3$ for extrapolating to shorter durations and $n = 1$ for extrapolating to longer durations. This approach would lead to 4- and 8-h AEGL-2 values of 0.01 and 0.007 ppm, respectively. These values are very close to the AEGL-3 values of 0.018 and 0.009 ppm for this compound, so this approach was not used to derive AEGL values.

AEGL-3 Values for Phenyl Isocyanate

10 min	30 min	1 h	4 h	8 h
0.036 ppm (0.18 mg/m ³)	0.036 ppm (0.18 mg/m ³)	0.029 ppm (0.14 mg/m ³)	0.018 ppm (0.088 mg/m ³)	0.0091 ppm (0.044 mg/m ³)

Reference: Bayer, AG. 1991a. Phenyl isocyanate; Untersuchungen zur akuten Inhalationstoxizität an der Ratte. Bercht- Nr. 20354. Studien-Nr. T7037386, Bayer AG Institut für Toxikologie.

Test species/Strain/Sex/Number: Rat, Wistar, 4 males and 4 females per group

Exposure route/Concentrations/Durations: Inhalation; 0, 2.1, 10.4, 20.8, 31.3, 64.6, 82.9, or 150.2 mg/m³ (0, 0.4, 2.2, 4.4, 6.6, 7.7, 17.4, and 31.3 ppm) for 4 h

Effects: Lethality

End point/Concentration/Rationale: Estimated lethality threshold (4-h BMCL₀₅ 1.64 ppm)

Uncertainty factors/Rationale:

Total uncertainty factor adjustment: 30

Interspecies: 3, because 6-h LC₅₀s for the related compound methyl isocyanate differed about two-fold between rats, mice, and guinea pigs (see Section 2.4). A factor of 3 is also consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Intraspecies: 10, is consistent with the one used for deriving AEGL-3 values for methyl isocyanate (NRC 2003).

Modifying factor: 3, to account for potential developmental toxicity of phenyl isocyanate on the basis of data on methyl isocyanate.

Animal-to-human dosimetric adjustment: Not applicable

Time scaling: $C^n \times t = k$; default values of $n = 1$ for extrapolating to longer durations and $n = 3$ for extrapolating to shorter durations. The 10-min AEGL-3 value was set equivalent to the 30-min value because of uncertainties associated with extrapolating a 4-h point of departure to a 10-min value (NRC 2001).

Data adequacy: Although lethal and nonlethal toxicity data are available for only one species, data on the related compound methyl isocyanate provide support for the AEGL values.

APPENDIX C

CATEGORY PLOTS FOR SELECTED MONOISOCYANATES




FIGURE C-1 Category plot of toxicity data and AEGL values for ethyl isocyanate.




FIGURE C-2 Category plot of toxicity data and AEGL values for cyclohexyl isocyanate.




FIGURE C-3 Category plot of toxicity data and AEGL values for *n*-butyl isocyanate.




FIGURE C-4 Category plot of toxicity data and AEGL values for phenyl isocyanate.

TABLE C-1 Data Used in Category Plot for Ethyl Isocyanate

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
AEGL-1				NR	10	AEGL	
AEGL-1				NR	30	AEGL	
AEGL-1				NR	60	AEGL	
AEGL-1				NR	240	AEGL	
AEGL-1				NR	480	AEGL	
AEGL-2				0.20	10	AEGL	
AEGL-2				0.065	30	AEGL	
AEGL-2				0.034	60	AEGL	
AEGL-2				0.0085	240	AEGL	
AEGL-2				0.0040	480	AEGL	
AEGL-3				0.60	10	AEGL	
AEGL-3				0.20	30	AEGL	
AEGL-3				0.10	60	AEGL	
AEGL-3				0.025	240	AEGL	
AEGL-3				0.013	480	AEGL	
Eastman Kodak 1964	Rat		1	27	360	2	
	Rat		1	82	360	3	Mortality (3/3)
	Rat		1	506	170	3	Mortality (3/3)

For category: 0 = no effect, 1 = discomfort, 2 = disabling, 3 = lethal; SL = some lethality.

TABLE C-2 Data Used in Category Plot for Cyclohexyl Isocyanate

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
AEGL-1				NR	10	AEGL	
AEGL-1				NR	30	AEGL	
AEGL-1				NR	60	AEGL	
AEGL-1				NR	240	AEGL	
AEGL-1				NR	480	AEGL	
AEGL-2				0.20	10	AEGL	
AEGL-2				0.065	30	AEGL	
AEGL-2				0.034	60	AEGL	
AEGL-2				0.0085	240	AEGL	
AEGL-2				0.0040	480	AEGL	
AEGL-3				0.60	10	AEGL	
AEGL-3				0.20	30	AEGL	
AEGL-3				0.10	60	AEGL	
AEGL-3				0.025	240	AEGL	
AEGL-3				0.013	480	AEGL	
Eastman Kodak 1990, 1992	Rat		1	17.79	360	3	Mortality (3/3), irritation, lacrimation, dyspnea, inflammation in lungs, congestion of kidney and liver.

(Continued)

TABLE C-2 Continued

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
	Rat		1	53.2	360	3	Mortality (3/3, two during exposure, one on day 12), irritation, lacrimation, dyspnea, inflammation in lungs, congestion of kidney and liver.
	Rat		1	1,017	360	3	Mortality (3/3, after 4 h), irritation, lacrimation, dyspnea, inflammation in lungs, congestion of kidney and liver, salivation, gasping.
Younger Laboratories 1974	Rat		1	1,401	150	3	Mortality (6/6), no other details
Crawford and Anderson 1974	Rat		1	Saturated	120	3	Mortality (8/8), no other details
Bayer AG 1980a	Rat		1	Saturated	3	2	No deaths, respiratory problems, enlarged lungs with red spots, fluid, lobulated liver.
	Rat		1	Saturated	10	3	Mortality (10/10, within 11 days), respiratory problems, enlarged lungs with red spots, fluid, lobulated liver.
	Rat		1	Saturated	60	3	Mortality (10/10, during exposure), respiratory problems, enlarged lungs with red spots, fluid, lobulated liver.

For category: 0 = no effect, 1 = discomfort, 2 = disabling, 3 = lethal; SL = some lethality.

TABLE C-3 Data Used in Category Plot for *n*-Butyl Isocyanate

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
AEGL-1				NR	10	AEGL	
AEGL-1				NR	30	AEGL	
AEGL-1				NR	60	AEGL	
AEGL-1				NR	240	AEGL	
AEGL-1				NR	480	AEGL	
AEGL-2				0.10	10	AEGL	
AEGL-2				0.10	30	AEGL	
AEGL-2				0.083	60	AEGL	
AEGL-2				0.053	240	AEGL	
AEGL-2				0.026	480	AEGL	
AEGL-3				0.31	10	AEGL	
AEGL-3				0.31	30	AEGL	
AEGL-3				0.25	60	AEGL	
AEGL-3				0.16	240	AEGL	
AEGL-3				0.078	480	AEGL	
Haskell 1989 (industrial hygiene report)	Human		1	0.01	480	1	
Haskell 1989 (industrial hygiene report)	Human		1	0.05	480	1	

(Continued) 267

TABLE C-3 Continued

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
IRDC 1965	Rat	Male	1	1.4	60	1	
IRDC 1965	Rat	Male	1	1.9	60	SL	
IRDC 1965	Rat	Male	1	2.7	60	SL	
IRDC 1965	Rat	Male	1	3.0	60	2	
IRDC 1965	Rat	Male	1	4.7	60	SL	
IRDC 1965	Rat	Male	1	5.4	60	SL	
IRDC 1965	Rat	Male	1	7.0	60	3	
IRDC 1965	Rat	Male	1	7.1	60	3	
IRDC 1965	Rat	Male	1	8.7	60	3	
Bayer AG 1978	Rat	Both	1	106	60	SL	LC ₅₀
Bayer AG 1978	Rat	Male	1	22.5	240	SL	LC ₅₀
Bayer AG 1978	Rat	Male	1	20.0	240	SL	LC ₅₀
Pauluhn and Eben 1991	Rat	Male	5	0.25	360	0	Multiple exposures; no clinical signs after 6 h/d for 5 d.
Pauluhn and Eben, 1991	Rat	Male	5	1.3	360	0	Multiple exposure study; no clinical signs after 6 h/d for 5 d.
Haskell 1968	Rat	Male	1	15.6	240	SL	LC ₅₀
IRDC 1965	Rat	Male	1	3.8	60	SL	LC ₅₀
Pauluhn et al. 1990	Rat	Male	1	1.9	240	1	Transient clinical signs (hypothermia, bradypnea, mucous membrane irritation).

Pauluhn et al. 1990	Rat	Male	1	14.0	240	3	Pulmonary function changes even at 4 wk post-exposure, pathologic findings in lungs.
Pauluhn et al. 1990	Rat	Male	1	5.9	240	2	Notable pulmonary effects that resolved within 1 wk.
Bayer AG 1978	Rat	Both	1	39	60	2	No mortality
Bayer AG 1978	Rat	Both	1	130	60	SL	Mortality (7/10)
Bayer AG 1978	Rat	Both	1	245	60	3	Mortality (10/10)
Bayer AG 1978	Rat	Both	1	94	60	SL	Mortality (3/20)
Bayer AG 1978	Rat	Both	1	222	60	SL	Mortality (19/20)
Bayer AG 1978	Rat	Both	1	233	60	3	Mortality (20/20)
Bayer AG 1978	Rat	Both	1	22	240	SL	Mortality (7/10)
Bayer AG 1978	Rat	Both	1	70	240	SL	Mortality (9/10)
Bayer AG 1978	Rat	Female	1	116	240	3	Mortality (5/5)

For category: 0 = no effect, 1 = discomfort, 2 = disabling, 3 = lethal; SL = some lethality.

TABLE C-4 Data Used in Category Plot for Phenyl Isocyanate

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
AEGL-1				NR	10	AEGL	
AEGL-1				NR	30	AEGL	
AEGL-1				NR	60	AEGL	
AEGL-1				NR	240	AEGL	
AEGL-1				NR	480	AEGL	
AEGL-2				0.012	10	AEGL	
AEGL-2				0.012	30	AEGL	
AEGL-2				0.0096	60	AEGL	
AEGL-2				0.0061	240	AEGL	
AEGL-2				0.0030	480	AEGL	
AEGL-3				0.036	10	AEGL	
AEGL-3				0.036	30	AEGL	
AEGL-3				0.029	60	AEGL	
AEGL-3				0.018	240	AEGL	
AEGL-3				0.0091	480	AEGL	
SA 1954	Rat		1	67	60	3	
SA 1954	Rat		1	67	120	3	
SA 1954	Rat		1	67	150	3	
Mobay 1978	Rat	Both	1	12.6	60	SL	LC ₅₀
ICI 1980	Rat	Both	1	3.9	60	SL	LC ₅₀

ICI 1977, Mobay 1978	Rat	Both	1	0.358	60	1	No clinical signs, minor histopathologic findings.
ICI 1977, Mobay 1978	Rat	Both	1	1.325	60	1	Minor clinical signs, pulmonary damage at necropsy.
ICI 1977; Mobay 1978	Rat	Both	1	1.45	60	2	Minor clinical signs, notable histopathologic effects.
ICI 1977, Mobay 1978	Rat	Both	1	2.167	60	SL	2/4 males, 2/4 females dead 5-12 d post-exposure.
ICI 1977, Mobay 1978	Rat	Both	1	4.368	60	SL	1/4 males, 3/4 females dead at 4-8 d post-exposure.
ICI 1977, Mobay 1978	Rat	Both	1	6.08	60	SL	2/4 males, 2/4 females dead at 8-13 d post-exposure.
ICI 1977, Mobay 1978	Rat	Both	1	7.942	60	3	100% lethality at 7-12 d post-exposure.
ICI 1977, Mobay 1978	Rat	Both	1	9.187	60	SL	4/4 males, 3/4 females dead at 1-14 d post-exposure.
ICI 1980	Rat	Both	11	0.05	360	0	No clinical signs, no histopathologic findings.
ICI 1980	Rat	Both	11	0.5	360	2	Respiratory distress on first day of exposure.
Bayer AG 1981	Rat	Both	1	1,600	3	3	Dead at 3-11 d.
Bayer AG 1981	Rat	Both	1	1,600	10	3	Dead at 3-24 h post-exposure.
Bayer AG 1981	Rat	Both	1	1,600	30	3	Dead at 32-59 min post-exposure.
SA 1954	Rat		1	29	240	1	No deaths but effects uncertain.

(Continued)

TABLE C-4 Continued

Source	Species	Sex	No. of Exposures	ppm	Minutes	Category	Comments
Bayer AG 1991b	Rat		5	0.03	240	0	No clinical signs after multiple exposures.
Bayer AG 1991b	Rat		5	0.10	240	0	No clinical signs after multiple exposures.
Bayer AG 1991b	Rat		5	0.70	240	1	Serous nasal discharge after 5 d, no findings for BAL and LDH analysis.
Pauluhn et al. 1995	Rat	Male	1	0.20	45	0	Threshold for respiratory tract irritation.
Pauluhn et al. 1995	Rat	Male	10	0.20	240	0	No clinical signs, no histopathologic findings.
Pauluhn et al. 1995	Rat	Male	10	0.80	240	0	No clinical signs, no histopathologic findings.
Pauluhn et al. 1995	Rat	Male	10	1.50	240	1	Signs of irritation, histopathologic findings after full exposure duration.
Bayer AG 1991a	Rat	Both	1	0.14	240	0	
Bayer AG 1991a	Rat	Both	1	1.1	240	0	
Bayer AG 1991a	Rat	Both	1	2.4	240	SL	Mortality (1/10)
Bayer AG 1991a	Rat	Both	1	3.1	240	0	
Bayer AG 1991a	Rat	Both	1	5.7	240	SL	Mortality (7/10)
Bayer AG 1991a	Rat	Both	1	9.7	240	3	Mortality (10/10)
Bayer AG 1991a	Rat	Both	1	18	240	3	Mortality (10/10)

For category: 0 = no effect, 1 = discomfort, 2 = disabling, 3 = lethal; SL = some lethality.

APPENDIX D

BENCHMARK DOSE MODELING FOR PHENYL ISOCYANATE




FIGURE D-1 Probit model (with 0.95 confidence level) of phenyl isocyanate data from 4-h lethality study (Bayer AG 1991a).

Probit Model. (Version: 3.2; Date: 10/28/2009)
 Input Data File: C:\Documents and Settings\BayerAG1991.dax.(d)
 Gnuplot Plotting File: C:\Documents and Settings\ BayerAG1991.plt
 Sat Mar 19 10:43:49 2011

BMDS Model Run

The form of the probability function is:

$$P[\text{response}] = \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Dose}),$$

where CumNorm(.) is the cumulative normal distribution function

Dependent variable = Col2

Independent variable = Col1

Slope parameter is not restricted

274

Acute Exposure Guideline Levels

Total number of observations = 6
 Total number of records with missing values = 0
 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values

Background = 0 Specified
 Intercept = -2.56468
 Slope = 0.462909

Asymptotic Correlation Matrix of Parameter Estimates

	Intercept	Slope
Intercept	1	-0.94
Slope	-0.94	1

(***The model parameter(s) background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

Parameter Estimates

Variable	Estimate	Standard Error	95.0% Wald Confidence Interval	
			Lower Confidence Limit	Upper Confidence Limit
Intercept	-3.51993	0.86272	-5.21083	-1.82903
Slope	0.69465	0.185701	0.330683	1.05862

Analysis of Deviance Table

Model	Log (likelihood)	No. of Parameters	Deviance	TestDF	P-value
Full model	-9.35947	6			
Fitted model	-10.8144	2	2.90976	4	0.573
Reduced model	-36.6519	1	54.5848	5	<0.0001

AIC: 25.6287

Goodness of Fit

Dose	Scaled				
	Estimated Probability	Expected	Observed	Size	Residual
0.1400	0.0003	0.003	0.000	10	-0.056
1.1100	0.0030	0.030	0.000	10	-0.173
2.4100	0.0325	0.325	1.000	10	1.205
3.1300	0.0892	0.892	0.000	10	-0.990
5.7500	0.6824	6.824	7.000	10	0.120
9.7100	0.9994	9.994	10.000	10	0.079

Chi-square = 2.49; DF = 4; P-value = 0.6472

Selected Monoisocyanates

275

Benchmark Dose Computation

Specified effect = 0.05

Risk Type = Extra risk

Confidence level = 0.95

BMC = 2.70217

BMCL₀₅ = 1.64064BMC₀₁

Probit Model. (Version: 3.2; Date: 10/28/2009)

Input Data File: C:\Documents and Settings\BayerAG1991a.dax(d)

Gnuplot Plotting File: C:\Documents and Settings\ BayerAG1991a.plt

Sat Mar 19 10:44:31 2011

BMDS_Model_Run

The form of the probability function is:

 $P[\text{response}] = \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Dose}),$

where CumNorm(.) is the cumulative normal distribution function

Dependent variable = Col2

Independent variable = Col1

Slope parameter is not restricted

Total number of observations = 6

Total number of records with missing values = 0

Maximum number of iterations = 250

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

Default Initial (and Specified) Parameter Values

Background = 0 Specified

Intercept = -2.56468

Slope = 0.462909

Asymptotic Correlation Matrix of Parameter Estimates

	Intercept	Slope
Intercept	1	-0.94
Slope	-0.94	1

(***The model parameter(s) –background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

Parameter Estimates

Variable	Estimate	Standard Error	95.0% Wald Confidence Interval	
			Lower Confidence Limit	Upper Confidence Limit
Intercept	-3.51993	0.86272	-5.21083	-1.82903
Slope	0.69465	0.185701	0.330683	1.05862

Analysis of Deviance Table

Model	Log (likelihood)	No. of Parameters	Deviance Test	DF	P-value
Full model	-9.35947	6			
Fitted model	-10.8144	2	2.90976	4	0.573
Reduced model	-36.6519	1	54.5848	5	<0.0001

AIC: 25.6287

Goodness of Fit

Dose	Estimated Probability	Scaled			
		Expected	Observed	Size	Residual
0.1400	0.0003	0.003	0.000	10	-0.056
1.1100	0.0030	0.030	0.000	10	-0.173
2.4100	0.0325	0.325	1.000	10	1.205
3.1300	0.0892	0.892	0.000	10	-0.990
5.7500	0.6824	6.824	7.000	10	0.120
9.7100	0.9994	9.994	10.000	10	0.079

Chi-square = 2.49; DF = 4; P-value = 0.6472

Benchmark Dose Computation

Specified effect = 0.01

Risk Type = Extra risk

Confidence level = 0.95

BMC₀₁ = 1.72968

BMCL = 0.591986